var title_f8_40_8832="Penile glans amputation";
var content_f8_40_8832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile glans amputation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 160px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Newborn penile glans amputation during circumcision and successful reattachment.",
"    <br>",
"     (A) Glans and foreskin amputated specimen.",
"     <br>",
"      (B) Graft anastomosis with stent.",
"      <br>",
"       (C) Three-month follow-up with good cosmesis and function.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: Gluckman G, Stoller M, Jacobs M, Kogan B. Pediatric urology: newborn penile glans amputation during circumcision and successful reattachment. J Urol 1995; 153:778. Copyright &copy; 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8832=[""].join("\n");
var outline_f8_40_8832=null;
var title_f8_40_8833="Vitreous cells in intraocular-CNS lymphoma";
var content_f8_40_8833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Vitreous cells in intraocular-central nervous system lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus photograph of the right eye shows large clumps of vitreous cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999; 106:1805. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8833=[""].join("\n");
var outline_f8_40_8833=null;
var title_f8_40_8834="Patient information: Esophageal varices (The Basics)";
var content_f8_40_8834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17197\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/39/8819\">",
"         Esophageal varices",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/9/12434\">",
"         Patient information: Screening for esophageal varices (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Esophageal varices (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/esophageal-varices-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3580083\">",
"      <span class=\"h1\">",
"       What are esophageal varices?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Esophageal varices are swollen blood vessels in the esophagus, which is the tube that connects the mouth to the stomach (",
"      <a class=\"graphic graphic_figure graphicRef63611 \" href=\"UTD.htm?8/39/8819\">",
"       figure 1",
"      </a>",
"      ). Esophageal varices often happen in people with serious liver disease, called &ldquo;cirrhosis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580098\">",
"      <span class=\"h1\">",
"       What are the symptoms of esophageal varices?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Esophageal varices do not cause symptoms until they leak or burst. This causes bleeding, which can be very serious. Signs of bleeding from esophageal varices include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vomiting blood",
"       </li>",
"       <li>",
"        Dark-colored or black bowel movements",
"       </li>",
"       <li>",
"        Feeling lightheaded",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you get one of more of these symptoms, call 9-1-1 for an ambulance. Do not drive yourself to the hospital or have another person drive you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580113\">",
"      <span class=\"h1\">",
"       Is there a test for esophageal varices?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. All people who have cirrhosis should have a test called an &ldquo;upper endoscopy&rdquo; to check for esophageal varices.",
"     </p>",
"     <p>",
"      For an upper endoscopy, the doctor puts a thin, flexible tube into your mouth down your throat and into your esophagus. The tube (called an endoscope) has a camera and a light on it. This allows the doctor to see inside your esophagus, stomach, and the first part of your intestine.",
"     </p>",
"     <p>",
"      Sometimes, doctors do an endoscopy using small capsule with a tiny camera inside. You swallow the capsule while lying on your right side and sip water every 30 seconds. The capsule sends photos of the lining of your esophagus and stomach to a device outside your body. A doctor then looks for any problems in the photos.",
"     </p>",
"     <p>",
"      If you have cirrhosis, you should have an upper endoscopy every 2 to 3 years. The doctor will check to see if you have new varices or if the ones you have are getting larger. Depending on what the doctor sees, he or she might even want to repeat the test more than once in 2 years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580128\">",
"      <span class=\"h1\">",
"       How are esophageal varices treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments that can make varices less likely to bleed include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Taking medicines called beta-blockers - These are also used to treat high blood pressure. Examples include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?42/4/43077?source=see_link\">",
"         propranolol",
"        </a>",
"        (brand name: Inderal&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31317?source=see_link\">",
"         nadolol",
"        </a>",
"        (brand name: Corgard&reg;).",
"       </li>",
"       <li>",
"        Losing weight, if you are overweight",
"       </li>",
"       <li>",
"        Avoiding alcohol",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have had bleeding from varices or are likely to have bleeding, your doctor can do a procedure during an endoscopy called &ldquo;variceal band ligation.&rdquo; He or she will place small rubber bands around the varices to stop the bleeding. You will need to take medicines that lower the amount of acid in your stomach while the varices heal. These over-the-counter medicines include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?31/61/32725?source=see_link\">",
"         Omeprazole",
"        </a>",
"        (sample brand name: Prilosec&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=see_link\">",
"         Lansoprazole",
"        </a>",
"        (sample brand name: Prevacid&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/40/13957?source=see_link\">",
"         Pantoprazole",
"        </a>",
"        (sample brand name: Protonix&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Variceal band ligation has to be repeated every 2 to 8 weeks until the varices are gone. Rarely, people who have severe bleeding need to have a procedure called a &ldquo;TIPS.&rdquo; For this procedure, a doctor inserts a thin tube through a vein in the neck and places the tube inside the liver. The tube helps blood to flow through the liver more easily. This lowers the blood pressure in the varices and helps stop bleeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580143\">",
"      <span class=\"h1\">",
"       Can esophageal varices be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treating the underlying liver disease that caused the cirrhosis might help prevent varices.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3580158\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=see_link\">",
"       Patient information: Screening for esophageal varices (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/40/8834?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17197 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8834=[""].join("\n");
var outline_f8_40_8834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580083\">",
"      What are esophageal varices?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580098\">",
"      What are the symptoms of esophageal varices?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580113\">",
"      Is there a test for esophageal varices?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580128\">",
"      How are esophageal varices treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580143\">",
"      Can esophageal varices be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3580158\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/39/8819\">",
"      Esophageal varices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8835="Echo image abdominal aorta";
var content_f8_40_8835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiographic image of the abdominal aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal (Ab) aorta (Ao) is seen from the subcostal long axis (panel A) and short axis views (panel B). In this thin patient the neural canal (NC) is seen through the intervertegral disc in the short axis view.",
"    <div class=\"footnotes\">",
"     RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8835=[""].join("\n");
var outline_f8_40_8835=null;
var title_f8_40_8836="Cysteamine (ophthalmic): Patient drug information";
var content_f8_40_8836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cysteamine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43122?source=see_link\">",
"     see \"Cysteamine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=see_link\">",
"     see \"Cysteamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15513771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015165",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of a protein called cystine from the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15513741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cysteamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15513743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15513774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697926",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright lights may bother you. Wear sunglasses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15513744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15513773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15513742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15513775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened bottles in the freezer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Each week, take out a new bottle from the freezer to use for that week. Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let bottle thaw for 24 hours before using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of thawed bottle not used after 7 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15513745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87036 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8836=[""].join("\n");
var outline_f8_40_8836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513771\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513741\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513743\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513774\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513744\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513773\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513742\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513775\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15513745\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43122?source=related_link\">",
"      Cysteamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/56/12164?source=related_link\">",
"      Cysteamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/49/16148?source=related_link\">",
"      Cysteamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=related_link\">",
"      Cysteamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8837="Hydralazine: Patient drug information";
var content_f8_40_8837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydralazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     see \"Hydralazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"     see \"Hydralazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydralazine&reg;;",
"     </li>",
"     <li>",
"      Apresoline&reg;;",
"     </li>",
"     <li>",
"      Novo-Hylazin;",
"     </li>",
"     <li>",
"      Nu-Hydral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydralazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have rheumatic heart disease that affected a heart valve.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the liquid (solution) closely. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12532 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8837=[""].join("\n");
var outline_f8_40_8837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179464\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018288\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018287\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018292\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018293\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018295\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018290\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018291\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018296\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018297\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=related_link\">",
"      Hydralazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=related_link\">",
"      Hydralazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8838="Protein in proximal tubule cell";
var content_f8_40_8838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Protein processing in proximal tubule cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Filtered proteins may be adsorbed to receptors, including megalin, on the apical surface of proximal tubular cells (A). Endosomes form from this membrane (B), and the first step in protein degradation requires acidification of the endosomal lumen through activity of the H+-ATPase as well as entry of chloride through the CLC-5 channel (C). Reabsorbed proteins are further degraded in the lysosomal pathway (D), while megalin and other membrane proteins are recycled back to the apical surface. In patients with Dent's disease, mutations inactivate the CLC-5 chloride channel and impair endosomal function. Reabsorption of glucose, phosphate, and amino acids are sodium-dependent processes involving specific apical membrane transporters (E). Reabsorption of one or more of these solutes is often also impaired in Dent's disease. The proximal tubular cell is also a site of production of 1,25 dihydroxyvitamin D, which occurs through the 1a-hydroxylase in mitochondria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scheinman SJ. Hosp Pract 2000; 35:49. Copyright &copy; 2000. The McGraw-Hill Companies, Inc. Illustration by Seward Hung.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8838=[""].join("\n");
var outline_f8_40_8838=null;
var title_f8_40_8839="Physiology of dyspnea";
var content_f8_40_8839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of dyspnea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8839/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8839/contributors\">",
"     Richard M Schwartzstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8839/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8839/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8839/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8839/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/40/8839/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breathing discomfort is one of the most common and distressing symptoms experienced by patients. While there are no symptom-specific data about the prevalence of this problem, the epidemiology of cardiac and pulmonary diseases indicates that the magnitude of the problem is large. Cardiac disease is the leading cause of death in the United States, and individuals with angina or myocardial infarction often experience breathlessness as the major (and sometimes sole) indicator that they are ill [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, asthma and chronic obstructive pulmonary disease (COPD) afflict approximately 25 million people in the United States, most of whom seek help from clinicians for relief of breathlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigations of the language of dyspnea suggest that this symptom represents a number of qualitatively distinct sensations, and that the words utilized by patients to describe their breathing discomfort may provide insights into the underlying pathophysiology of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Furthermore, there is a growing recognition that one must distinguish between a \"sensation\" (the neural activation resulting from the stimulation of a receptor) and a \"perception\" (the reaction of the individual to that sensation) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In addition, for a given intensity of a breathing sensation, the unpleasantness of the sensation may vary with the stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A consensus statement of the American Thoracic Society has defined dyspnea as \"a term used to characterize a subjective experience of breathing discomfort that is comprised of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors, and may induce secondary physiological and behavioral responses\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The respiratory system is designed to maintain homeostasis with respect to gas exchange (adequate oxygenation) and the acid-base status of the organism (adjust PaCO",
"    <sub>",
"     2",
"    </sub>",
"    to maintain normal pH). Derangements in oxygenation as well as acidemia lead to breathing discomfort. However, the development of dyspnea is a complex phenomenon which, in many patients, is the result of stimulation of a variety of mechanoreceptors throughout the upper airway, lungs, and chest wall, and which must also account for the sensations that arise when there is a mechanical load on the system. The origins of dyspnea associated with the inadequate delivery of oxygen to, or utilization by, peripheral muscles are less well understood, but deserve consideration as well.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the mechanisms, assessment, and management of dyspnea, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The pathophysiology of dyspnea will be reviewed here. Factors affecting the control of ventilation and disorders of ventilation, and an approach to a patient with dyspnea, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link\">",
"     \"Disorders of ventilatory control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCREASED OUTPUT FROM THE RESPIRATORY CENTERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most conditions that are associated with respiratory discomfort are characterized by increases in ventilation in response to derangements in ventilation-perfusion matching, increases in dead space, the presence of metabolic acidosis, or stimulation of pulmonary or chest wall receptors. For many years it was believed that this increase in stimulation of the respiratory centers and the resultant augmentation of activity of the ventilatory muscles was responsible for dyspnea. However, subsequent data suggest that the intensity of respiratory discomfort for a given level of ventilation may vary considerably depending upon the nature of the stimulus giving rise to the hyperpnea, and that stimulation of chemoreceptors can produce dyspnea even in the absence of activation of the respiratory muscles (",
"    <a class=\"graphic graphic_figure graphicRef69322 \" href=\"UTD.htm?30/15/30967\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chemoreceptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral chemoreceptors, located in the carotid bodies and aortic arch, sense changes in the partial pressure of oxygen in arterial blood and are also stimulated by acidosis and hypercapnia. The central chemoreceptors, located in the medulla, respond to changes in pH and PCO",
"    <sub>",
"     2",
"    </sub>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .) Acute hypercapnia is generally a much stronger stimulus for respiratory discomfort than is acute hypoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;While acute hypercapnia typically leads to brisk increases in ventilation, dyspnea can result from hypercapnia among ventilator-dependent C1-2 quadriplegics who lack functioning respiratory muscles, and in normal subjects paralyzed with neuromuscular blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In a different experimental model, normal subjects maintaining a targeted ventilation experienced greater dyspnea when made hypercapnic than when eucapnic conditions were maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/13\">",
"     13",
"    </a>",
"    ]. These results are consistent with the notion that there are direct projections from the chemoreceptors to the sensory cortex, ie, there is a \"corollary discharge\" or neural discharge to the sensory cortex that is generated simultaneously with and in proportion to the brainstem neural output to the respiratory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hypoxemia is also associated with increases in ventilation and respiratory discomfort. While the data supporting a direct role for hypoxic stimulation of chemoreceptors in the production of dyspnea are less clear than with hypercapnia, it seems likely that hypoxemia can produce breathing discomfort independently of changes in ventilation. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects exercising under hypoxic conditions experience more dyspnea than when performing the same activity while breathing room air, and less dyspnea when breathing 100 percent oxygen&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results have been obtained in patients with COPD who exercise with varying degrees of hypoxia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progressive hypoxemia in normal subjects is associated with greater breathing discomfort than comparable degrees of ventilation resulting from exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/17\">",
"       17",
"      </a>",
"      ], demonstrating an effect of hypoxemia on dyspnea that is independent of minute ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STIMULATION OF MECHANORECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout the airways, lungs, and chest wall are a variety of receptors that assist the body in monitoring changes in pressure, flow, and volume in the respiratory system. Information from these receptors is integrated by the central nervous system in a manner that modulates the intensity of dyspnea. However, in some cases, most notably the \"chest tightness\" associated with bronchoconstriction, the receptors may be the primary source of the sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Upper airway receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulation of receptors in the face and upper airway, which are largely innervated by the trigeminal nerve, can",
"    <strong>",
"     reduce",
"    </strong>",
"    the intensity of dyspnea. As examples, cold air directed against the face increases breathholding time and reduces the respiratory discomfort associated with breathing against an inspiratory load [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Presumed stimulation of flow or temperature receptors by the inhalation of cold air reduces exertional dyspnea and ventilation in patients with COPD, while reductions in upper airway receptor stimulation achieved with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or by the inhalation of warm, humidified air worsen respiratory discomfort in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung is populated by three major categories of receptors that transmit information relevant to respiratory sensation to the central nervous system via the vagus nerve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slowly adapting receptors, also known as pulmonary stretch receptors, are activated by an increase in tension in the walls of airways, thereby providing information about increases in lung volume.",
"     </li>",
"     <li>",
"      Rapidly adapting receptors or irritant receptors are stimulated by rapid changes in lung volume, direct mechanical stimuli, or inhalation of irritant particulate matter or chemicals such as histamine.",
"     </li>",
"     <li>",
"      C-fibers are unmyelinated afferent nerve fibers that originate in J-receptors located in small airways and near alveolar capillaries; they are stimulated by mechanical and chemical factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The configuration of these receptors is such that limitations of the movement of the respiratory system exacerbate dyspnea in a variety of experimental conditions, including breathholding and acute hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Restriction of tidal volume associated with hyperinflation may also contribute to the discomfort experienced by patients with emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    is hypothesized to stimulate pulmonary stretch receptors. It has been shown to reduce dyspnea in healthy subjects in whom dyspnea was induced using a large resistive load plus hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, dyspnea associated with acute hypercapnia and a restricted tidal volume, as well as the breathlessness associated with exercise, are ameliorated by inhaled furosemide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulation of pulmonary receptors may provoke the dyspnea of asthma. While the work of breathing is increased in patients with acute bronchoconstriction due to changes in airways resistance and hyperinflation, the intensity of dyspnea is greater with acute bronchoconstriction than with external resistive loads at comparable degrees of airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and the quality of the discomfort is different [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/3,4,18,19,31\">",
"     3,4,18,19,31",
"    </a>",
"    ]. Breathing against an external load leads to a sensation of increased \"effort\" or \"work\" of breathing, while acute bronchospasm is associated with a sensation of \"chest tightness or constriction.\" Furthermore, the inhalation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    appears to blunt the dyspnea of bronchoconstriction, consistent with the hypothesis that stimulation of pulmonary receptors is contributing to the breathing discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/18\">",
"     18",
"    </a>",
"    ]. Activation of pulmonary receptors may also play a role in the dyspnea of acute pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chest wall receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information from muscle spindles and tendon organs within the chest wall is also important to the perception of dyspnea. Muscle spindles function as length or stretch receptors, while tendon organs monitor force generation. As noted above, constrained chest wall movement exacerbates dyspnea associated with acute hypercapnia, although the relative roles of pulmonary and chest wall receptors are difficult to ascertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have studied the importance of chest wall receptors on dyspnea by applying mechanical vibrators to the intercostal space, resulting in stimulation of muscle spindles. In-phase vibration, ie, vibration applied to the inspiratory muscles during inspiration, reduces dyspnea in normal subjects made breathless with hypercapnia and an external resistive load [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/33\">",
"     33",
"    </a>",
"    ]. Similar results were obtained in patients with COPD at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/34\">",
"     34",
"    </a>",
"    ] and while breathing carbon dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/35\">",
"     35",
"    </a>",
"    ], although vibration appeared to have little effect at higher degrees of discomfort associated with exercise on a cycle ergometer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/35\">",
"     35",
"    </a>",
"    ]. Timing of the stimulation also appears to be important because out-of-phase vibration, ie, vibration of inspiratory muscles during expiration, heightens the intensity of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/36\">",
"     36",
"    </a>",
"    ]. It is important to note that the vibration used in these studies might also have stimulated pulmonary receptors.",
"   </p>",
"   <p>",
"    While stimulation of chest wall receptors likely plays a role in the detection of changes in thoracic expansion, pulmonary receptors are sufficient to monitor lung volume. Patients with cervical spinal cord injury, for example, in whom information from chest wall receptors is interrupted before reaching the brain, can detect small changes in tidal volume and experience respiratory discomfort when tidal volumes are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MECHANICAL LOADING OF THE RESPIRATORY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of cardiopulmonary diseases are associated with an increased mechanical load due to changes in airways resistance or pulmonary or chest wall compliance. To achieve a given tidal volume under these conditions, the brain must generate a greater neural output to the ventilatory muscles.",
"   </p>",
"   <p>",
"    Outgoing motor commands to the ventilatory muscles probably are associated with a corollary discharge to the sensory cortex, which is perceived as a \"sense of effort\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/39\">",
"     39",
"    </a>",
"    ]. The sense of effort appears to be a function of the ratio of the pressure generated by the ventilatory muscles on a given breath to the maximal pressure achievable by the muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, the sense of effort may increase because there is an obstruction to flow and the intrathoracic pressure generated on each breath is high, or because the pressure-generating capacity of the muscles is reduced, as is seen in the presence of muscle fatigue, myopathy, or hyperinflation.",
"   </p>",
"   <p>",
"    Normal subjects maintaining a constant ventilatory target experience less effort but more dyspnea when hypercapnic than eucapnic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/13\">",
"     13",
"    </a>",
"    ]. While mechanical loading and the effort to breathe are common features of dyspnea in many disease states, they do not explain respiratory discomfort in all settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEUROMECHANICAL DISSOCIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efferent neural impulses exit the brain and proceed to the ventilatory muscles, where they trigger contraction, generation of negative pressure within the thorax, and inspiratory air flow with expansion of the lungs and chest wall. If there is a mechanical load suddenly imposed on the respiratory system with no change in the neurologic command to the ventilatory muscles, the muscles will not shorten appropriately for the tension being generated, intrathoracic pressures will be less negative than normal, inspiratory flow will be reduced, and tidal volume will be diminished.",
"   </p>",
"   <p>",
"    Although the exact means by which the body makes the comparison between what is expected under normal conditions for a given efferent message and the actual outcome of that message remains unclear, the mismatch between the two (termed \"efferent-reafferent dissociation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/41\">",
"     41",
"    </a>",
"    ] or \"neuromechanical dissociation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/42\">",
"     42",
"    </a>",
"    ]) appears to worsen the intensity of dyspnea. This mechanism may in part explain the dyspnea associated with experimentally constrained ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], hyperinflation in COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/27,42,43\">",
"     27,42,43",
"    </a>",
"    ], hyperinflation in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/44\">",
"     44",
"    </a>",
"    ], and in some patients on mechanical ventilators [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/45\">",
"     45",
"    </a>",
"    ]. It may also explain the amelioration of dyspnea with chest wall vibration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/33-35\">",
"     33-35",
"    </a>",
"    ] or a flow of air on the face [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these last two examples, receptors in the chest wall and in the distribution of the trigeminal nerve are stimulated exogenously. It is believed that such stimulation, by conveying to the brain information that would indicate the respiratory system had achieved greater flows or volume displacement than actually had occurred, would lead to reduced discrepancy between the efferent neural command and the \"apparent\" mechanical response, thereby diminishing the intensity of dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     IMPAIRED OXYGEN DELIVERY OR UTILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia and cardiovascular deconditioning are two common clinical conditions that are associated with exertional dyspnea and do not readily fit into the categories outlined above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate to severe anemia typically experience breathing discomfort with light exercise despite the absence of a gas exchange abnormality or mechanical loading of the respiratory system. The response of the body to the reduced oxygen-carrying capacity of the blood is to increase cardiac output. This may necessitate an increase in left ventricular end-diastolic pressure with consequent increases in pulmonary venous pressures, the development of interstitial edema, and stimulation of C-fibers. However, tachycardia, rather than increased stroke volume, is often the first response of the cardiovascular system, and it is unclear to what extent intracardiac and pulmonary vascular pressures rise in this setting.",
"   </p>",
"   <p>",
"    An alternative explanation is that the reduced delivery of oxygen to the metabolically active muscles may lead to the development of a localized metabolic acidosis and the stimulation of \"ergoreceptors\" in the peripheral muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Another possibility is that the ventilatory muscles are impaired by the reduced oxygen delivery, which could lead to muscle fatigue under conditions of sustained hyperpnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Deconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;An individual's fitness is determined by the ability of the cardiovascular system to deliver oxygenated blood to the muscles and by the capability of the muscles to utilize that oxygen via aerobic metabolism to engage in mechanical work. Exercise programs improve fitness by training the heart to generate a greater cardiac output and by inducing enzyme changes in skeletal muscle to improve the efficiency of oxygen use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with chronic lung disease assume a sedentary lifestyle and become deconditioned; functional capabilities may be determined more by their level of fitness than by their underlying respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/48\">",
"     48",
"    </a>",
"    ]. Dyspnea on exertion in these individuals may result primarily from the utilization of anaerobic metabolism at low levels of exercise, development of a metabolic acidosis, and increased neural output from the respiratory centers. Whether the development of localized acidosis and stimulation of ergoreceptors also play a role in this situation remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEURAL ACTIVATION ASSOCIATED WITH BREATHING DISCOMFORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators have begun to employ positron emission tomography and magnetic resonance imaging as tools to localize regions of the brain that are activated when breathing discomfort is induced experimentally. Acute hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/49\">",
"     49",
"    </a>",
"    ], restriction of tidal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/50\">",
"     50",
"    </a>",
"    ], and imposition of external resistive loads [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8839/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] have all led to activation of areas within the limbic system and, to a lesser degree, within the brainstem. These areas of the brain also are likely to be involved in the perception of uncomfortable sensations such as pain and hunger. Whether future studies utilizing this technique will identify clearly delineated neural pathways for different types of dyspnea remains to be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breathing discomfort is a complex set of sensations which clinicians group under the term dyspnea. The physiologic mechanisms underlying these sensations are varied, and multiple mechanisms may be present in a given patient (",
"    <a class=\"graphic graphic_figure graphicRef69322 \" href=\"UTD.htm?30/15/30967\">",
"     figure 1",
"    </a>",
"    ). The individual with COPD, for example, may experience breathlessness because of hypoxemia (increased neural input from peripheral chemoreceptors and output from the respiratory centers), increased airways resistance and hyperinflation (mechanical loading), and neuromechanical dissociation. In the presence of an acute respiratory infection or volume overload, stimulation of pulmonary receptors may also play a role. Appreciation for the complexity of the system allows one to better understand the changes in symptoms that occur over time in a given patient, and permits a more rational therapeutic program to ameliorate a potentially disabling symptom.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/1\">",
"      Cook DG, Shaper AG. Breathlessness, lung function and the risk of heart attack. Eur Heart J 1988; 9:1215.",
"     </a>",
"    </li>",
"    <li>",
"     Higgins M. Epidemiology of obstructive pulmonary disease. In: Principles and Practice of Pulmonary Rehabilitation, Casaburi R, Petty TL (Eds), WB Saunders, Philadelphia 1993. p.10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/3\">",
"      Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/4\">",
"      Elliott MW, Adams L, Cockcroft A, et al. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 1991; 144:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/5\">",
"      Mahler DA, Harver A, Lentine T, et al. Descriptors of breathlessness in cardiorespiratory diseases. Am J Respir Crit Care Med 1996; 154:1357.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartzstein RM. The language of dyspnea. In: Dyspnea: Mechanisms, measurement, and management, Mahler DA, O'Donnell DE (Eds), Marcel Dekker, New York 2005. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/7\">",
"      Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/8\">",
"      Scano G, Ambrosino N. Pathophysiology of dyspnea. Lung 2002; 180:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/9\">",
"      Jensen D, Webb KA, Davies GA, O'Donnell DE. Mechanisms of activity-related breathlessness in healthy human pregnancy. Eur J Appl Physiol 2009; 106:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/10\">",
"      Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med 2008; 177:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/11\">",
"      Banzett RB, Lansing RW, Reid MB, et al. 'Air hunger' arising from increased PCO2 in mechanically ventilated quadriplegics. Respir Physiol 1989; 76:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/12\">",
"      Banzett RB, Lansing RW, Brown R, et al. 'Air hunger' from increased PCO2 persists after complete neuromuscular block in humans. Respir Physiol 1990; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/13\">",
"      Demediuk BH, Manning H, Lilly J, et al. Dissociation between dyspnea and respiratory effort. Am Rev Respir Dis 1992; 146:1222.",
"     </a>",
"    </li>",
"    <li>",
"     Banzett RB, Lansing RW. Respiratory sensations arising from pulmonary and chemoreceptor afferents. In: Respiratory Sensation, Adams L, Guz A (Eds), Marcel Dekker Inc, New York 1996. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/15\">",
"      Chronos N, Adams L, Guz A. Effect of hyperoxia and hypoxia on exercise-induced breathlessness in normal subjects. Clin Sci (Lond) 1988; 74:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/16\">",
"      Lane R, Cockcroft A, Adams L, Guz A. Arterial oxygen saturation and breathlessness in patients with chronic obstructive airways disease. Clin Sci (Lond) 1987; 72:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/17\">",
"      Adams L, Lane R, Shea SA, et al. Breathlessness during different forms of ventilatory stimulation: a study of mechanisms in normal subjects and respiratory patients. Clin Sci (Lond) 1985; 69:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/18\">",
"      Taguchi O, Kikuchi Y, Hida W, et al. Effects of bronchoconstriction and external resistive loading on the sensation of dyspnea. J Appl Physiol 1991; 71:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/19\">",
"      Moy ML, Woodrow Weiss J, Sparrow D, et al. Quality of dyspnea in bronchoconstriction differs from external resistive loads. Am J Respir Crit Care Med 2000; 162:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/20\">",
"      McBride B, Whitelaw WA. A physiological stimulus to upper airway receptors in humans. J Appl Physiol 1981; 51:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/21\">",
"      Schwartzstein RM, Lahive K, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987; 136:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/22\">",
"      Spence DP, Graham DR, Ahmed J, et al. Does cold air affect exercise capacity and dyspnea in stable chronic obstructive pulmonary disease? Chest 1993; 103:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/23\">",
"      Simon PM, Basner RC, Weinberger SE, et al. Oral mucosal stimulation modulates intensity of breathlessness induced in normal subjects. Am Rev Respir Dis 1991; 144:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/24\">",
"      FOWLER WS. Breaking point of breath-holding. J Appl Physiol 1954; 6:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/25\">",
"      Chonan T, Mulholland MB, Cherniack NS, Altose MD. Effects of voluntary constraining of thoracic displacement during hypercapnia. J Appl Physiol 1987; 63:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/26\">",
"      Schwartzstein RM, Simon PM, Weiss JW, et al. Breathlessness induced by dissociation between ventilation and chemical drive. Am Rev Respir Dis 1989; 139:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/27\">",
"      O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/28\">",
"      Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/29\">",
"      Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol 2007; 156:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/30\">",
"      Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008; 63:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/31\">",
"      Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis 1989; 140:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/32\">",
"      Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995; 333:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/33\">",
"      Manning HL, Basner R, Ringler J, et al. Effect of chest wall vibration on breathlessness in normal subjects. J Appl Physiol 1991; 71:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/34\">",
"      Sibuya M, Yamada M, Kanamaru A, et al. Effect of chest wall vibration on dyspnea in patients with chronic respiratory disease. Am J Respir Crit Care Med 1994; 149:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/35\">",
"      Cristiano LM, Schwartzstein RM. Effect of chest wall vibration on dyspnea during hypercapnia and exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/36\">",
"      Homma I, Obata T, Sibuya M, Uchida M. Gate mechanism in breathlessness caused by chest wall vibration in humans. J Appl Physiol 1984; 56:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/37\">",
"      Banzett RB, Lansing RW, Brown R. High-level quadriplegics perceive lung volume change. J Appl Physiol 1987; 62:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/38\">",
"      Manning HL, Shea SA, Schwartzstein RM, et al. Reduced tidal volume increases 'air hunger' at fixed PCO2 in ventilated quadriplegics. Respir Physiol 1992; 90:19.",
"     </a>",
"    </li>",
"    <li>",
"     McCloskey DI. Corollary discharges: Motor commands and perception. In: Handbook of Physiology, Section I, The Nervous System, Brookahrt JM, Mountcastle VB (Eds), American Physiological Society, Bethesda 1981. Vol II, p.1415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/40\">",
"      Killian KJ, Gandevia SC, Summers E, Campbell EJ. Effect of increased lung volume on perception of breathlessness, effort, and tension. J Appl Physiol 1984; 57:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/41\">",
"      Schwartzstein RM, Manning HL, Weiss JW, Weinberger SE. Dyspnea: a sensory experience. Lung 1990; 168:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/42\">",
"      O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993; 148:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/43\">",
"      O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007; 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/44\">",
"      Lougheed MD, Fisher T, O'Donnell DE. Dynamic hyperinflation during bronchoconstriction in asthma: implications for symptom perception. Chest 2006; 130:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/45\">",
"      Manning HL, Molinary EJ, Leiter JC. Effect of inspiratory flow rate on respiratory sensation and pattern of breathing. Am J Respir Crit Care Med 1995; 151:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/46\">",
"      Clark AL, Piepoli M, Coats AJ. Skeletal muscle and the control of ventilation on exercise: evidence for metabolic receptors. Eur J Clin Invest 1995; 25:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/47\">",
"      Clark A, Volterrani M, Swan JW, et al. Leg blood flow, metabolism and exercise capacity in chronic stable heart failure. Int J Cardiol 1996; 55:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/48\">",
"      Killian KJ, Leblanc P, Martin DH, et al. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 1992; 146:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/49\">",
"      Corfield DR, Fink GR, Ramsay SC, et al. Evidence for limbic system activation during CO2-stimulated breathing in man. J Physiol 1995; 488 ( Pt 1):77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/50\">",
"      Banzett RB, Mulnier HE, Murphy K, et al. Breathlessness in humans activates insular cortex. Neuroreport 2000; 11:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/51\">",
"      Peiffer C, Poline JB, Thivard L, et al. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med 2001; 163:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8839/abstract/52\">",
"      von Leupoldt A, Sommer T, Kegat S, et al. Down-regulation of insular cortex responses to dyspnea and pain in asthma. Am J Respir Crit Care Med 2009; 180:232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1427 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8839=[""].join("\n");
var outline_f8_40_8839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCREASED OUTPUT FROM THE RESPIRATORY CENTERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chemoreceptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STIMULATION OF MECHANORECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Upper airway receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chest wall receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MECHANICAL LOADING OF THE RESPIRATORY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEUROMECHANICAL DISSOCIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IMPAIRED OXYGEN DELIVERY OR UTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Deconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEURAL ACTIVATION ASSOCIATED WITH BREATHING DISCOMFORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1427|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/15/30967\" title=\"figure 1\">",
"      Origin of dyspnea sensation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8840="Bromocriptine: Drug information";
var content_f8_40_8840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bromocriptine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/23/35189?source=see_link\">",
"    see \"Bromocriptine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=see_link\">",
"    see \"Bromocriptine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cycloset&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg; SnapTabs&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Bromocriptine;",
"     </li>",
"     <li>",
"      PMS-Bromocriptine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Dopamine Agonist;",
"     </li>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acromegaly:",
"     </b>",
"     Oral: Initial: 1.25-2.5 mg daily increasing by 1.25-2.5 mg daily as necessary every 3-7 days; usual dose: 20-30 mg/day (maximum: 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"     Oral: Initial: 1.25-2.5 mg/day; may be increased by 2.5 mg/day as tolerated every 2-7 days until optimal response (range: 2.5-15 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinsonism:",
"     </b>",
"     Oral: 1.25 mg twice daily, increased by 2.5 mg/day in 2- to 4-week intervals as needed (maximum: 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes (Cycloset&reg;):",
"     </b>",
"     Oral: Initial: 0.8 mg once daily; may increase at weekly intervals in 0.8 mg increments as tolerated; usual dose: 1.6-4.8 mg/day (maximum: 4.8 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroleptic malignant syndrome (unlabeled use):",
"     </b>",
"     Oral: 2.5 mg (orally or via gastric tube) every 8-12 hours, increased to a maximum of 45 mg/day, if needed; continue therapy until NMS is controlled, then taper slowly (Gortney, 2009; Strawn, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=see_link\">",
"      see \"Bromocriptine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 11-15 years (based on limited information): Initial: 1.25-2.5 mg daily. Dosage may be increased as tolerated to achieve a therapeutic response (range 2.5-10 mg daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F142576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F142577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, adjustment may be necessary due to extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parlodel&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycloset&reg;: 0.8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parlodel&reg; SnapTabs&reg;: 2.5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Cycloset&reg;",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food to decrease GI distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cycloset&reg;: Administer within 2 hours of waking in the morning.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperprolactinemia associated with amenorrhea with or without galactorrhea, infertility, or hypogonadism; treatment of prolactin-secreting adenomas; treatment of acromegaly; treatment of Parkinson's disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cycloset&reg;: Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F142612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuroleptic malignant syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bromocriptine may be confused with benztropine, brimonidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cycloset&reg; may be confused with Glyset&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Parlodel&reg; may be confused with pindolol, Provera&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency of adverse effects may vary by dose and/or indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (including postural/orthostatic), Raynaud's syndrome exacerbation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, lightheadedness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (4%; in combination with sulfonylureas or other antidiabetic agents: 7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, diarrhea, dyspepsia, GI bleeding, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Digital vasospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined, postmarketing, and/or case reports (Limited to important or life-threatening): Alopecia, blindness (transient), bradycardia, cardiac valve fibrosis, cerebrospinal fluid rhinorrhea, confusion, constrictive pericarditis, depression, dysphagia, epileptiform seizure, ergotism, erythromelalgia, gastrointestinal ulceration, hallucinations, hypertension (postpartum), insomnia, MI (postpartum), pericardial effusion, peripheral edema, pleural effusion, pleural/pulmonary fibrosis, pleurisy, psychomotor agitation/excitation, psychosis, retroperitoneal fibrosis, seizures (postpartum), status epilepticus (postpartum), stroke (postpartum), sudden onset of sleep, tachycardia, urinary incontinence, urinary retention, ventricular tachycardia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Withdrawal reactions: Abrupt discontinuation has resulted in rare cases of a withdrawal reaction with symptoms similar to neuroleptic malignant syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with dopamine agonists: Impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bromocriptine, ergot alkaloids, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Additional contraindications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Parlodel&reg;: Uncontrolled hypertension; pregnancy (risk to benefit evaluation must be performed in women who become pregnant during treatment for acromegaly, prolactinoma, or Parkinson's disease - hypertension during treatment should generally result in efforts to withdraw); postpartum women with a history of coronary artery disease or other severe cardiovascular conditions (unless withdrawal of medication is medically contraindicated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cycloset&reg;: Syncopal migraine; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids and derivatives have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Symptomatic hypotension may occur in a significant number of patients. In addition, hypertension, seizures, MI, and stroke have been rarely associated with therapy. Severe headache or visual changes may precede events. The onset of reactions may be immediate or delayed (often may occur in the second week of therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling/spending, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy  reverses these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Sudden sleep onset and somnolence have been reported with use, primarily in patients with Parkinson&rsquo;s disease. Patients must be cautioned about performing tasks which require mental alertness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acromegaly: Appropriate use: In the treatment of acromegaly, discontinuation is recommended if tumor expansion occurs during therapy. Digital vasospasm (cold sensitive) may occur in some patients with acromegaly; may require dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (myocardial infarction, arrhythmia). Should not be used postpartum in women with coronary artery disease or other cardiovascular disease; use to control or prevent lactation or in patients with uncontrolled hypertension is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Use with caution in patients with dementia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetic ketoacidosis (DKA): Should not be used in patients with DKA due to lack of efficacy in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Macroadenomas: Discontinuation of therapy in patients with macroadenomas has been associated with rapid regrowth of tumor and increased prolactin serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Safety has not been established for use &gt;2 years in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with extreme caution or avoid use in patients with psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease: Safety and efficacy have not been established in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Type 1 diabetes mellitus: Should not be used in patients with type 1 diabetes mellitus (insulin dependent, IDDM) due to lack of efficacy in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antidiabetic agents: There is limited efficacy of use in combination with thiazolidinediones or in combination with insulin. Combination therapy with other hypoglycemic agents may increase risk for hypoglycemic events; dose reduction of concomitant hypoglycemics may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antihypertensives: Concurrent antihypertensives or drugs which may alter blood pressure should be used with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors and/or major CYP3A4 substrates (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Levodopa: Concurrent use with levodopa has been associated with an increased risk of hallucinations; consider dosage reduction and/or discontinuation in patients with hallucinations. Hallucinations may require weeks to months before resolution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and effectiveness have not been established in children &lt;11 years of age for pituitary adenoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Patients who receive during and immediately following pregnancy as a continuation of previous therapy (eg, acromegaly) should be closely monitored for cardiovascular effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interchangeability (Cycloset&reg;): Due to a difference in the formulation and resulting pharmacokinetics of Cycloset&reg; (\"quick-release\" tablet) compared to other formulations of bromocriptine, interchangeability with any other bromocriptine product is not recommended in the setting of type 2 diabetes mellitus management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use; gradual dosage reduction is recommended when discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pituitary function evaluation: Complete evaluation of pituitary function should be completed prior to initiation of treatment of any hyperprolactinemia-associated dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual monitoring: Monitoring and careful evaluation of visual changes during the treatment of hyperprolactinemia is recommended to differentiate between tumor shrinkage and traction on the optic chiasm; rapidly progressing visual field loss requires neurosurgical consultation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: May enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Bromocriptine may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F142567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase GI side effects or ethanol intolerance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease bromocriptine levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2798907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No evidence of teratogenicity or fetal toxicity in animal studies. Bromocriptine is used for ovulation induction in women with hyperprolactinemia. In general, therapy should be discontinued if pregnancy is confirmed unless needed for treatment of macroprolactinoma. Data collected from women taking bromocriptine during pregnancy suggest the incidence of birth defects is not increased with use. However, the majority of women discontinued use within 8 weeks of pregnancy. Women not seeking pregnancy should be advised to use appropriate contraception.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2798909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A previous indication for prevention of postpartum lactation was withdrawn voluntarily by the manufacturer following reports of serious adverse reactions, including stroke, MI, seizures, and severe hypertension. Use during breast-feeding is specifically contraindicated in the product labeling for Cycloset&reg;. Use in postpartum women with a history of coronary artery disease or other severe cardiovascular conditions is specifically contraindicated in the product labeling for Parlodel&reg; (unless withdrawal of medication is medically contraindicated). Based on the risk/benefit assessment, other treatments should be considered for lactation suppression.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F142560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F142559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Bromocriptine Mesylate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $171.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Parlodel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $322.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bromocriptine Mesylate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $65.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cycloset Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg (200): $499.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Parlodel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $200.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure closely as well as hepatic, hematopoietic, and cardiovascular function; visual field monitoring is recommended (prolactinoma); pregnancy test during amenorrheic period; growth hormone (acromegaly) and prolactin levels; Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and serum glucose (type 2 diabetes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11257968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bromocriptine (NZ);",
"     </li>",
"     <li>",
"      Aspen Bromocriptine (ZA);",
"     </li>",
"     <li>",
"      Bagren (BR);",
"     </li>",
"     <li>",
"      Baimoting (CL);",
"     </li>",
"     <li>",
"      Barlolin (TW);",
"     </li>",
"     <li>",
"      Brameston (BB, BM, BS, BZ, EC, GY, JM, PR, SG, SR, TT);",
"     </li>",
"     <li>",
"      Bromergon (HK, HR, TH);",
"     </li>",
"     <li>",
"      Bromo-Kin (FR);",
"     </li>",
"     <li>",
"      Bromocorn (PL);",
"     </li>",
"     <li>",
"      Bromocriptin-Richter (HU);",
"     </li>",
"     <li>",
"      Bromocriptina (CO);",
"     </li>",
"     <li>",
"      Butin (TW);",
"     </li>",
"     <li>",
"      Cripsa (ID);",
"     </li>",
"     <li>",
"      Demil (TW);",
"     </li>",
"     <li>",
"      Deprolac (TW);",
"     </li>",
"     <li>",
"      Kripton (AU);",
"     </li>",
"     <li>",
"      Medocriptine (BG);",
"     </li>",
"     <li>",
"      Parilac (IL);",
"     </li>",
"     <li>",
"      Parlodel (AE, AR, AT, AU, BD, BE, BF, BH, BJ, BR, CH, CI, CO, CY, CZ, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, IE, IN, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Pravidel (DE, SE);",
"     </li>",
"     <li>",
"      Protinal (IN);",
"     </li>",
"     <li>",
"      Ronalin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Serocryptin (AE, BH, CY, EG, HU, IQ, IR, IT, JO, KW, LB, LY, MY, OM, PE, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Suplac (TH);",
"     </li>",
"     <li>",
"      Umprel (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Semisynthetic ergot alkaloid derivative and a dopamine receptor agonist which activates postsynaptic dopamine receptors in the tuberoinfundibular (inhibiting pituitary prolactin secretion) and nigrostriatal pathways (enhancing coordinated motor control).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In the treatment of type 2 diabetes mellitus, the mechanism of action is unknown; however, bromocriptine is believed to affect circadian rhythms which are mediated, in part, by dopaminergic activity, and are believed to play a role in obesity and insulin resistance. It is postulated that bromocriptine (when administered during the morning and released into the systemic circulation in a rapid, &lsquo;pulse-like&rsquo; dose) may reset hypothalamic circadian activities which have been altered by obesity, thereby resulting in the reversal of insulin resistance and decreases in glucose production, without increasing serum insulin concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Parlodel&reg;: Prolactin decreasing effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~61L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 96% (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via CYP3A; extensive first-pass biotransformation (Cycloset&reg;: ~93%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Cycloset&reg;: 65% to 95%; Parlodel&reg;: 28%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Cycloset&reg;: ~6 hours; Parlodel&reg;: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Cycloset&reg;: 53 minutes; Parlodel&reg;: 0.5-4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (82%); urine (2% to 6% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dackis CA and Gold MS, &ldquo;Bromocriptine as Treatment of Cocaine Abuse,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985, 1(8438):1151-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot AN, van Dongen PW, Vree TB, et al, &ldquo;Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(4):523-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/9806101/pubmed\" id=\"9806101\" target=\"_blank\">",
"        9806101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaziano JM, Cincotta AH, O&rsquo;Connor CM, et al, &ldquo;Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2010, 33(7):1503-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/20332352/pubmed\" id=\"20332352\" target=\"_blank\">",
"        20332352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gortney JS, Fagan A, and Kissack JC, &ldquo;Neuroleptic Malignant Syndrome Secondary to Quetiapine,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(4):785-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/19299325/pubmed\" id=\"19299325\" target=\"_blank\">",
"        19299325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koller WC, Silver DE, and Lieberman A, &ldquo;An Algorithm for the Management of Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(12 Suppl 10):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/8290041/pubmed\" id=\"8290041\" target=\"_blank\">",
"        8290041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Melmed S and Braunstein GD, &ldquo;Bromocriptine and Pleuropulmonary Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):258-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/2916870/pubmed\" id=\"2916870\" target=\"_blank\">",
"        2916870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molitch ME, &ldquo;Management of Prolactinomas During Pregnancy,&rdquo;",
"      <i>",
"       J Reprod Med",
"      </i>",
"      , 1999, 44(12 Suppl):1121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/10649822/pubmed\" id=\"10649822\" target=\"_blank\">",
"        10649822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgans D, &ldquo;Re: Parlodel,&rdquo;",
"      <i>",
"       Aust N Z J Obstet Gynaecol",
"      </i>",
"      , 1995, 35(2):228-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkes D, &ldquo;Drug Therapy: Bromocriptine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1979, 301(16):873-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/384250/pubmed\" id=\"384250\" target=\"_blank\">",
"        384250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pijl H, Ohashi S, Matsuda M, et al, &ldquo;Bromocriptine: A Novel Approach to the Treatment of Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2000, 23(8):1154-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/10937514/pubmed\" id=\"10937514\" target=\"_blank\">",
"        10937514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):2-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/9222162/pubmed\" id=\"9222162\" target=\"_blank\">",
"        9222162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strawn JR, Keck PE Jr, and Caroff SN, \"Neuroleptic Malignant Syndrome,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(6):870-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/17541044/pubmed\" id=\"17541044\" target=\"_blank\">",
"        17541044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts RL, &ldquo;The Role of Dopamine Agonists in Early Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):34-48.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/40/8840/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9164 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8840=[""].join("\n");
var outline_f8_40_8840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142616\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142575\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142592\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142576\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682299\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142577\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142550\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142536\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460170\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142553\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142612\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142623\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142614\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142556\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142540\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142610\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142567\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142546\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2798907\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142579\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2798909\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142560\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142559\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142548\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257968\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142561\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142539\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142555\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9164|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/23/35189?source=related_link\">",
"      Bromocriptine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=related_link\">",
"      Bromocriptine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8841="Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis";
var content_f8_40_8841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8841/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8841/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8841/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/40/8841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) is the most common hemolytic anemia due to a red cell membrane defect. It is a result of heterogeneous alterations in genes which encode for proteins involved in the vertical associations which tie the red cell's inner membrane skeleton to its outer lipid bilayer (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ). This topic will review the determinants of hemolysis and the molecular pathogenesis and genetics of HS. The clinical presentation, diagnosis and treatment of HS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H508524\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resistance and elastic deformability of red cells are due to a cytoskeleton that laminates the lipid bilayer and to proteins which provide vertical association of the cytoskeleton with the bilayer. A number of interconnected proteins are involved in the coupling of the cytoskeleton to the lipid bilayer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spectrin (composed of alpha, beta heterodimers)",
"     </li>",
"     <li>",
"      Ankyrin",
"     </li>",
"     <li>",
"      Pallidin (band 4.2)",
"     </li>",
"     <li>",
"      Band 4.1 (protein 4.1)",
"     </li>",
"     <li>",
"      Band 3 protein (the anion exchanger, AE1)",
"     </li>",
"     <li>",
"      RhAG (the Rh-associated glycoprotein)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spectrin deficiency is often present in HS. This is true even if the primary mutation is in a nonspectrin protein, because alterations in these proteins adversely affect the assembly of spectrin onto the membrane skeleton. The clinical severity of the disorder correlates well with the degree of spectrin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Spherocyte formation and subsequent hemolysis is due to red cell membrane instability and conditioning by the spleen (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ). Often more than one red cell membrane protein is deficient in HS. As shown in HS mouse models, aberrant protein sorting during erythroid enucleation, a consequence of the primary RBC membrane defect, appears to be an important explanation for these secondary deficiencies. For example, in ankyrin deficient mice, band 3, RhAG, and GPA all show increased sorting to the extruded nucleus, thus explaining their deficiency in reticulocytes and mature RBC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Membrane instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectrin-deficient spherocytes have decreased membrane mechanical stability, which probably contributes to red cell destruction in severe cases. However, the central abnormality that defines spherocytosis is progressive loss of elements of the lipid bilayer by microvesiculation, reflecting the weakened vertical association of the bilayer with the membrane skeleton. Loss of surface area without concomitant loss of volume imposes the spherocytic shape on affected red cells, reducing their ability to deform and pass through constricted regions of the microcirculation. There is evidence that membrane loss is present as early as the reticulocyte stage (",
"    <a class=\"graphic graphic_table graphicRef54945 \" href=\"UTD.htm?1/50/1836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/6\">",
"     6",
"    </a>",
"    ], although fully developed spherocytes appear to be limited to mature red cells (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Splenic conditioning'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Two hypotheses have been advanced to explain how deficiencies or qualitative defects in these membrane proteins lead to vesiculation and membrane loss. In the first, spectrin deficiency acts directly on the bilayer to create areas of weakness that allow membrane loss. In the second, the integrity of the bilayer is maintained by band 3; deficiency of this protein or its dispersion as a result of abnormalities in the underlying membrane skeletal proteins is the proximate cause of vesiculation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are important differences in the microvesicles shed by band 3 deficient HS red cells and those shed by",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficient cells; the former do not contain band 3, but the latter do. Elegant studies have suggested that the loss of band 3 molecules reduces IgG binding to band 3 clusters in",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficient HS cells and thus reduces opsonization and immune mediated destruction by naturally occurring antibodies. No equivalent loss of band 3 by vesiculation occurs in band 3 deficient HS red cells. These observations appear to explain the greater improvement in post-splenectomy survival noted in",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficient HS red cells than is seen in band 3 deficient HS red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell ion transport abnormalities associated with hereditary spherocytosis are to some extent dependent upon the particular membrane protein abnormality present. As an example, anion transport (primarily chloride-bicarbonate exchange) is decreased in band 3 deficiency (band 3 is the anion transporter), normal in",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficiency, and increased in isolated pallidin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, increased passive permeability to monovalent cations (sodium and potassium) is a general feature of human spherocytes with any of these three membrane protein defects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/9\">",
"     9",
"    </a>",
"    ] and is also found in spherocytic mice with deficiencies of ankyrin or spectrin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests an activation of the Gardos channel in transgenic mice with protein",
"    <span class=\"nowrap\">",
"     4.1/4.2",
"    </span>",
"    deficiency or band 3 deficiency that appears to protect against hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/11\">",
"     11",
"    </a>",
"    ]. This effect is paradoxical in that erythrocyte dehydration accompanying activation of this channel normally has an adverse effect on red cell survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Splenic conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen plays a crucial role in the generation and destruction of hereditary spherocytes. Since reticulocytes in HS are not spherocytic, the spherocytic shape change must appear after reticulocyte maturation in the circulation. Repeated passages through the splenic cords, a process termed splenic conditioning, promotes membrane lipid loss, leading to a reduction in surface area and a progressively more spheroid red cell. Because of this process, red cells obtained from the splenic vein have greater osmotic fragility than those obtained from the splenic artery. The more spheroidal the red cell, the greater the likelihood that its lack of deformability will prevent its passage through the narrow fenestrations of the splenic cords. The latter has been studied quantitatively using human spleens perfused in vitro with red cells with various degrees of surface area loss induced by treatment with lysophosphatidylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/12\">",
"     12",
"    </a>",
"    ]. Red cells with 18 percent or more loss of surface area were rapidly and completely entrapped by the spleen. Since the internal viscosity and membrane protein composition remained unchanged in these experimentally manipulated red cells, the ability of the spleen to recognize alterations in the surface area:volume ratio and entrap altered cells was clearly demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detained in the spleen, the red cell is subjected to an acidotic, metabolically unfavorable environment where oxidants are prevalent and phagocytic reticuloendothelial cells are ubiquitous. In addition, secondary lesions, such as 2,3-DPG depletion, occur in this setting. Membrane protein methylation, a marker for damage, is greatly increased in spectrin-deficient spherocytes before splenectomy but drops to near normal levels after splenectomy. Thus, this abnormality may be a marker for splenic conditioning. In comparison, little or no membrane methylation occurs when the molecular abnormality causing spherocytosis involves band 3 instead of spectrin, suggesting that cytoskeletal damage is not a component of this type of spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H509478\">",
"    <span class=\"h3\">",
"     Effect of splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central importance of the spleen in the destruction of spherocytes in HS is clearly seen when the spleen is removed surgically. This procedure virtually eliminates hemolysis and anemia in moderately severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/6\">",
"     6",
"    </a>",
"    ], and eliminates the need for transfusion and partially corrects the anemia in severe cases. However, spherocytes are still present, indicating that factors other than splenic conditioning can lead to spherocytosis in the absence of the spleen (",
"    <a class=\"graphic graphic_table graphicRef54945 \" href=\"UTD.htm?1/50/1836\">",
"     table 1",
"    </a>",
"    ). One such factor is the early loss of membrane that occurs in reticulocytes from HS patients irrespective of prior splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, hereditary spherocytosis is the clinical consequence of mutations in the genes encoding ankyrin, band 3, alpha spectrin, beta spectrin, RhAG or pallidin (protein 4.2) (",
"    <a class=\"graphic graphic_figure graphicRef55451 \" href=\"UTD.htm?32/40/33414\">",
"     figure 2",
"    </a>",
"    ). The central role of mutations of these membrane proteins in the origin of spherocytosis has been demonstrated in transgenic mice that completely lack band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] or protein 4.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/17\">",
"     17",
"    </a>",
"    ] and by naturally occurring mutations that create severe",
"    <span class=\"nowrap\">",
"     ankyrin/spectrin",
"    </span>",
"    or severe spectrin deficiency in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/18\">",
"     18",
"    </a>",
"    ] and complete band 3 deficiency in cattle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/19\">",
"     19",
"    </a>",
"    ]. That specific mutations of alpha-spectrin can affect the quantity or function of other components of the membrane skeleton or integral membrane proteins has become evident through careful analysis of mice with HS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/20\">",
"     20",
"    </a>",
"    ]. Protein 4.1 deficiency is associated with elliptocytosis and, because of membrane instability, the presence of fragmented cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mice harboring a mutation in the erythroid specific transcription factor KFL1 exhibit a dominantly inherited severe neonatal anemia with features of HS. Their RBC are deficient in multiple membrane proteins (alpha and beta spectrin, ankyrin, and band 3) as well as a complete absence of protein 4.1a [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As yet, no human HS examples associated with KLF1 mutations have been identified.",
"   </p>",
"   <p>",
"    Family studies indicate autosomal dominant inheritance in about 75 percent of patients, with recessive inheritance occurring in most of the remaining patients. However, a significant number of patients with hematologically normal parents and presumed recessive disease prove to harbor de novo mutations, the majority of which will exhibit dominant inheritance in subsequent generations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/25-30\">",
"     25-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One extensive survey of 166 HS kindreds in Portugal found spectrin or",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficiency in 60 percent, band 3 deficiency in 23 percent, isolated pallidin deficiency in 2 percent, and no membrane protein abnormalities in the remaining 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/31\">",
"     31",
"    </a>",
"    ]. Other series have reported similar findings in Northern European populations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/18,32-35\">",
"     18,32-35",
"    </a>",
"    ]. Rh-null disease accounts for at most 1 percent of HS cases",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ankyrin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankyrin/spectrin",
"    deficiency is usually associated with the autosomal dominant form of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/18\">",
"     18",
"    </a>",
"    ]. The responsible mutation is in the ankyrin gene; spectrin deficiency is secondary to the reduced amount of ankyrin present in the membrane. Ankyrin is the principal binding site for spectrin on the red cell membrane; as a result, ankyrin deficiency leads to decreased incorporation of spectrin on the membrane. The degree of hemolysis varies widely from patient to patient, even though the molecular defect appears to be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/33\">",
"     33",
"    </a>",
"    ]. This observation indicates that factors other than the primary gene defect determine the severity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately one-third of patients with ankyrin deficiency, one ankyrin mRNA allele is virtually missing due to deletion, frameshift, or nonsense mutations that alter transcription, processing, or stability of ankyrin mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ]. A chromosomal deletion on the short arm of chromosome 8 that included the ankyrin gene locus has been reported in seven patients with HS, mental retardation, and physical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/39\">",
"     39",
"    </a>",
"    ]. These individuals also lack one ankyrin mRNA allele.",
"   </p>",
"   <p>",
"    Other ankyrin mutations in dominant hereditary spherocytosis include truncated variants and one nonexpressed isoform [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Ankyrin mutations associated with recessive HS have been missense mutations or mutations in the promoter region [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. All told, 55 distinct ankyrin mutations have been reported in human hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Band 3 defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental studies suggest that a main function of band 3 protein is prevention of membrane surface loss rather than assembly of the membrane skeleton. Thus, targeted mutagenesis to generate RBCs without band 3 results in spherocytosis and hemolysis but no change in the skeletal architecture or components [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations are applicable to humans, since heterozygous band 3 mutations that result in the absence or decrease of the mutant protein in the red cell membrane are responsible for 15 to 25 percent of cases of hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/33,44\">",
"     33,44",
"    </a>",
"    ]. In these patients, there is always an associated and roughly proportional deficiency of pallidin in the membrane; spectrin deficiency is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/31\">",
"     31",
"    </a>",
"    ]. Inheritance is autosomal dominant and the clinical picture is that of mild, usually compensated, hemolytic anemia. Red cell anion transport is typically diminished in proportion to the reduction in band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other natural band 3 mutations are known that are clinically benign. These include the mutant band 3 present in Southeast Asian ovalocytosis, a condition which provides protection against cerebral malaria in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Resistance to malaria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several kindreds of autosomal dominant distal renal tubular acidosis have been associated with mutations in erythrocyte band 3 (anion exchanger 1, AE1, SLC4A1) and abnormalities in red cell ion transport. These cases, however, do not have hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], although some patients with HS and a band 3 protein mutation show abnormal renal bicarbonate handling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/50\">",
"     50",
"    </a>",
"    ]. Mutations in the AE1 gene do not appear to be generally responsible for autosomal recessive distal renal tubular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/48\">",
"     48",
"    </a>",
"    ], although two subjects with homozygous band 3 mutations, severe HS and distal renal tubular acidosis have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H42786914#H42786914\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Effect on potassium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with",
"    <span class=\"nowrap\">",
"     ankyrin/spectrin",
"    </span>",
"    deficiency, many band 3 deficient individuals harbor frameshift or nonsense mutations that are associated with complete or near complete absence of the mutant allele mRNA in reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/31,34,50,55,56\">",
"     31,34,50,55,56",
"    </a>",
"    ]. Others have recombination or missense mutations involving highly conserved regions of the band 3 molecule. In these patients, reticulocyte mRNA is normal in amount, but little or no mutant band 3 is present in the membrane. The exact abnormality in band 3 biosynthesis, transport, or assembly in the membrane responsible for the absence of band 3 is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/31,34,45,56-59\">",
"     31,34,45,56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of band 3 deficiency and the clinical severity of these dominantly inherited mutations are sometimes increased by the simultaneous inheritance of a second band 3 mutation in trans [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These mutations produce very mild band 3 deficiency when inherited alone, and are clinically silent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spectrin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectrin deficiency in the membrane may be due to alpha- or beta-spectrin gene defects but, as noted above, is more often secondary to ankyrin gene defects. Synthesis of beta-spectrin is rate limiting for the assembly of the spectrin tetramer, while alpha-spectrin is synthesized in excess. Thus, deficiency or dysfunction of a single beta-spectrin allele is sufficient to cause spherocytosis (dominant inheritance) while both alpha-spectrin alleles must be affected to cause the disease (recessive inheritance). Missense mutations of beta-spectrin associated with recessive inheritance have also been reported. These are presumably milder mutations that either do not completely abolish transcription and translation or lead to production of normal or near normal amounts of a dysfunctional protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Beta-spectrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mutations of beta-spectrin are associated with mild to moderate autosomal dominant HS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/61\">",
"     61",
"    </a>",
"    ]. Numerous null mutations (missense or frameshift mutations that silence the affected allele) have been found in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Other mutations include a missense mutation that generates a dysfunctional molecule with decreased binding affinity for protein 4.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/64\">",
"     64",
"    </a>",
"    ] and a mutation in which mutant spectrin is synthesized but inefficiently incorporated into the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], and several that decrease levels of beta-spectrin mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Alpha-spectrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recessive inheritance of two alpha-spectrin deficiency mutations is associated with severe HS with markedly reduced membrane spectrin levels. Both homozygotes for a single alpha-spectrin mutation and compound heterozygotes for two different alpha-spectrin mutations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/68\">",
"     68",
"    </a>",
"    ]. In one hereditary spherocytosis pedigree, the two alpha-spectrin mutations were found to be alpha spectrin Prague, a truncated alpha spectrin, and alpha spectrin Lepra, a splice site mutation that causes a frameshift, premature termination of translation, and greatly reduced production of alpha-spectrin. Indirect evidence suggests that alpha-spectrin Lepra may be found in as many as 50 percent of kindreds with recessive HS and marked spectrin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha-spectrin Lely, another mutation that is associated with alpha-spectrin deficiency, does not reduce the output of alpha spectrin polypeptides sufficiently to lead to spherocytosis, even when inherited in the homozygous state [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/68\">",
"     68",
"    </a>",
"    ]. Although not yet described, if co-inherited with a severe alpha-spectrin deficiency in trans, alpha-spectrin Lely is theoretically capable of leading to recessive spectrin deficiency HS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pallidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis associated with isolated pallidin (protein 4.2) deficiency is an autosomal recessive condition that is usually found in individuals of Japanese ancestry. In addition, protein 4.2-null mice have mild hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/17\">",
"     17",
"    </a>",
"    ]. Absence of pallidin has been shown by electron microscopy to result in a distorted red cell cytoskeletal network [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous missense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/71-73\">",
"     71-73",
"    </a>",
"    ] and several splicing mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/74,75\">",
"     74,75",
"    </a>",
"    ] of the pallidin gene have been discovered. Isolated pallidin deficiency should be distinguished from spherocytosis associated with band 3 deficiency. In the latter disease, the mutation and primary protein deficiency involve band 3 with secondary deficiency of pallidin polypeptide, even though no pallidin mutation is present.",
"   </p>",
"   <p>",
"    In a third type of pallidin deficiency, mutations in band 3 occur that adversely affect the binding of pallidin to band 3 producing pallidin deficiency in the membrane and spherocytosis even though band 3 levels remain normal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. Details of the binding abnormalities have not yet been fully elucidated, but they do not appear to involve major changes in the stability or structure of band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rh-associated glycoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rh-associated glycoprotein (RhAG) binds to ankyrin and contributes to the vertical stability of the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/81\">",
"     81",
"    </a>",
"    ]. Mutations of RhAG and loss of this interaction are thought to underlie the hemolytic anemia and sphero-stomatocytosis seen in Rh-null disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8841/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link&amp;anchor=H11#H11\">",
"     \"Stomatocytosis\", section on 'Rh-null disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H14#H14\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Rh blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H508400\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) is a result of alterations in genes encoding for proteins which tie the red blood cell (RBC) inner membrane skeleton to its outer lipid bilayer (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ). These include ankyrin, band 3 (the anion exchanger), alpha spectrin, beta spectrin, Rh-associated glycoprotein, and pallidin (protein 4.2) (",
"    <a class=\"graphic graphic_figure graphicRef55451 \" href=\"UTD.htm?32/40/33414\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spectrin deficiency is often present in HS, even if the primary mutation is in a nonspectrin protein, since alterations in these other proteins adversely affect the assembly of spectrin onto the membrane skeleton. (See",
"      <a class=\"local\" href=\"#H508524\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spectrin-deficient RBCs have decreased membrane mechanical stability, with progressive loss of the lipid bilayer by microvesiculation. This loss of surface area without loss of volume imposes the spherocytic shape on affected red cells (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Membrane instability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repeated passages through the splenic cords (splenic conditioning) promote further membrane lipid loss, leading to a progressively more spheroid red cell, preventing its passage through the narrow fenestrations of the splenic cords, and ultimately resulting in red cell destruction in that organ. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Splenic conditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The central importance of the spleen is clearly seen following splenectomy, which virtually eliminates hemolysis and anemia in moderately severe cases, and eliminates the need for transfusion in severe cases. (See",
"      <a class=\"local\" href=\"#H509478\">",
"       'Effect of splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/1\">",
"      Agre P, Orringer EP, Bennett V. Deficient red-cell spectrin in severe, recessively inherited spherocytosis. N Engl J Med 1982; 306:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/2\">",
"      Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004; 126:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/3\">",
"      An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/4\">",
"      Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/5\">",
"      Salomao M, Chen K, Villalobos J, et al. Hereditary spherocytosis and hereditary elliptocytosis: aberrant protein sorting during erythroblast enucleation. Blood 2010; 116:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/6\">",
"      Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.",
"     </a>",
"    </li>",
"    <li>",
"     Lux SE, Palek J. Disorders of the red cell membrane. In: Blood. Principles and Practice of Hematology, Handin RI, Lux SE, Stossel TP (Eds), Lippincott, Philadelphia 1995. p.1701.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/8\">",
"      Reliene R, Mariani M, Zanella A, et al. Splenectomy prolongs in vivo survival of erythrocytes differently in spectrin/ankyrin- and band 3-deficient hereditary spherocytosis. Blood 2002; 100:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/9\">",
"      De Franceschi L, Olivieri O, Miraglia del Giudice E, et al. Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects. Am J Hematol 1997; 55:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/10\">",
"      Joiner CH, Franco RS, Jiang M, et al. Increased cation permeability in mutant mouse red blood cells with defective membrane skeletons. Blood 1995; 86:4307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/11\">",
"      De Franceschi L, Rivera A, Fleming MD, et al. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood 2005; 106:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/12\">",
"      Safeukui I, Buffet PA, Deplaine G, et al. Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen. Blood 2012; 120:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/13\">",
"      Schrier SL. What does the spleen see? Blood 2012; 120:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/14\">",
"      Ingrosso D, D'Angelo S, Perrotta S, et al. Cytoskeletal behaviour in spectrin and in band 3 deficient spherocytic red cells: evidence for differentiated splenic conditioning role. Br J Haematol 1996; 93:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/15\">",
"      Peters LL, Shivdasani RA, Liu SC, et al. Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton. Cell 1996; 86:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/16\">",
"      Southgate CD, Chishti AH, Mitchell B, et al. Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Nat Genet 1996; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/17\">",
"      Peters LL, Jindel HK, Gwynn B, et al. Mild spherocytosis and altered red cell ion transport in protein 4. 2-null mice. J Clin Invest 1999; 103:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/18\">",
"      Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol 1993; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/19\">",
"      Inaba M, Yawata A, Koshino I, et al. Defective anion transport and marked spherocytosis with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle due to a nonsense mutation. J Clin Invest 1996; 97:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/20\">",
"      Robledo RF, Lambert AJ, Birkenmeier CS, et al. Analysis of novel sph (spherocytosis) alleles in mice reveals allele-specific loss of band 3 and adducin in alpha-spectrin-deficient red cells. Blood 2010; 115:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/21\">",
"      Tchernia G, Mohandas N, Shohet SB. Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary elliptocytosis. Implications for erythrocyte membrane stability. J Clin Invest 1981; 68:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/22\">",
"      Takakuwa Y, Tchernia G, Rossi M, et al. Restoration of normal membrane stability to unstable protein 4.1-deficient erythrocyte membranes by incorporation of purified protein 4.1. J Clin Invest 1986; 78:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/23\">",
"      White RA, Sokolovsky IV, Britt MI, et al. Hematologic characterization and chromosomal localization of the novel dominantly inherited mouse hemolytic anemia, neonatal anemia (Nan). Blood Cells Mol Dis 2009; 43:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/24\">",
"      Heruth DP, Hawkins T, Logsdon DP, et al. Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model. Genomics 2010; 96:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/25\">",
"      Randon J, Miraglia del Giudice E, Bozon M, et al. Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio. Br J Haematol 1997; 96:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/26\">",
"      del Giudice EM, Hayette S, Bozon M, et al. Ankyrin Napoli: a de novo deletional frameshift mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis. Br J Haematol 1996; 93:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/27\">",
"      Morl&eacute; L, Bozon M, Alloisio N, et al. Ankyrin Bugey: a de novo deletional frameshift variant in exon 6 of the ankyrin gene associated with spherocytosis. Am J Hematol 1997; 54:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/28\">",
"      Miraglia del Giudice E, Francese M, Nobili B, et al. High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis. J Pediatr 1998; 132:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/29\">",
"      Miraglia del Giudice E, Lombardi C, Francese M, et al. Frequent de novo monoallelic expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and isolated spectrin deficiency. Br J Haematol 1998; 101:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/30\">",
"      Miraglia del Giudice E, Nobili B, Francese M, et al. Clinical and molecular evaluation of non-dominant hereditary spherocytosis. Br J Haematol 2001; 112:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/31\">",
"      Jarolim P, Murray JL, Rubin HL, et al. Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 1996; 88:4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/32\">",
"      Miraglia del Giudice E, Iolascon A, Pinto L, et al. Erythrocyte membrane protein alterations underlying clinical heterogeneity in hereditary spherocytosis. Br J Haematol 1994; 88:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/33\">",
"      Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 1996; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/34\">",
"      Dhermy D, Galand C, Bournier O, et al. Heterogenous band 3 deficiency in hereditary spherocytosis related to different band 3 gene defects. Br J Haematol 1997; 98:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/35\">",
"      Mariani M, Barcellini W, Vercellati C, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 2008; 93:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/36\">",
"      Rocha S, Costa E, Rocha-Pereira P, et al. Erythrocyte membrane protein destabilization versus clinical outcome in 160 Portuguese Hereditary Spherocytosis patients. Br J Haematol 2010; 149:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/37\">",
"      Jarolim P, Rubin HL, Brabec V, Palek J. Comparison of the ankyrin (AC)n microsatellites in genomic DNA and mRNA reveals absence of one ankyrin mRNA allele in 20% of patients with hereditary spherocytosis. Blood 1995; 85:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/38\">",
"      Gallagher PG, Ferreira JD, Costa FF, et al. A recurrent frameshift mutation of the ankyrin gene associated with severe hereditary spherocytosis. Br J Haematol 2000; 111:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/39\">",
"      Okamoto N, Wada Y, Nakamura Y, et al. Hereditary spherocytic anemia with deletion of the short arm of chromosome 8. Am J Med Genet 1995; 58:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/40\">",
"      Jarolim P, Rubin HL, Brabec V, et al. Abnormal alternative splicing of erythroid ankyrin mRNA in two kindred with hereditary spherocytosis (ankyrin Prague and ankyrin Rakovnik). Blood 1993; 82(Suppl 1):5a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/41\">",
"      Hayette S, Carr&eacute; G, Bozon M, et al. Two distinct truncated variants of ankyrin associated with hereditary spherocytosis. Am J Hematol 1998; 58:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/42\">",
"      Gallagher PG, Steiner LA, Liem RI, et al. Mutation of a barrier insulator in the human ankyrin-1 gene is associated with hereditary spherocytosis. J Clin Invest 2010; 120:4453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/43\">",
"      Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis 2005; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/44\">",
"      Tanner MJ. The structure and function of band 3 (AE1): recent developments (review). Mol Membr Biol 1997; 14:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/45\">",
"      Jarolim P, Rubin HL, Brabec V, et al. Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood 1995; 85:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/46\">",
"      Jarolim P, Palek J, Amato D, et al. Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A 1991; 88:11022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/47\">",
"      Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/48\">",
"      Karet FE, Gainza FJ, Gy&ouml;ry AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 1998; 95:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/49\">",
"      Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem 1998; 273:6380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/50\">",
"      Lima PR, Gontijo JA, Lopes de Faria JB, et al. Band 3 Campinas: a novel splicing mutation in the band 3 gene (AE1) associated with hereditary spherocytosis, hyperactivity of Na+/Li+ countertransport and an abnormal renal bicarbonate handling. Blood 1997; 90:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/51\">",
"      Ribeiro ML, Alloisio N, Almeida H, et al. Severe hereditary spherocytosis and distal renal tubular acidosis associated with the total absence of band 3. Blood 2000; 96:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/52\">",
"      Toye AM, Williamson RC, Khanfar M, et al. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111:5380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/53\">",
"      Chu C, Woods N, Sawasdee N, et al. Band 3 Edmonton I, a novel mutant of the anion exchanger 1 causing spherocytosis and distal renal tubular acidosis. Biochem J 2010; 426:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/54\">",
"      Chang YH, Shaw CF, Jian SH, et al. Compound mutations in human anion exchanger 1 are associated with complete distal renal tubular acidosis and hereditary spherocytosis. Kidney Int 2009; 76:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/55\">",
"      Jenkins PB, Abou-Alfa GK, Dhermy D, et al. A nonsense mutation in the erythrocyte band 3 gene associated with decreased mRNA accumulation in a kindred with dominant hereditary spherocytosis. J Clin Invest 1996; 97:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/56\">",
"      Miraglia del Giudice E, Vallier A, Maillet P, et al. Novel band 3 variants (bands 3 Foggia, Napoli I and Napoli II) associated with hereditary spherocytosis and band 3 deficiency: status of the D38A polymorphism within the EPB3 locus. Br J Haematol 1997; 96:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/57\">",
"      Maillet P, Vallier A, Reinhart WH, et al. Band 3 Chur: a variant associated with band 3-deficient hereditary spherocytosis and substitution in a highly conserved position of transmembrane segment 11. Br J Haematol 1995; 91:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/58\">",
"      Bianchi P, Zanella A, Alloisio N, et al. A variant of the EPB3 gene of the anti-Lepore type in hereditary spherocytosis. Br J Haematol 1997; 98:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/59\">",
"      Alloisio N, Texier P, Vallier A, et al. Modulation of clinical expression and band 3 deficiency in hereditary spherocytosis. Blood 1997; 90:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/60\">",
"      Alloisio N, Maillet P, Carr&eacute; G, et al. Hereditary spherocytosis with band 3 deficiency. Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by a low-expression allele occurring in trans (allele Genas). Blood 1996; 88:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/61\">",
"      Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/62\">",
"      Dhermy D, Galand C, Bournier O, et al. Hereditary spherocytosis with spectrin deficiency related to null mutations of the beta-spectrin gene. Blood Cells Mol Dis 1998; 24:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/63\">",
"      Garbarz M, Galand C, Bibas D, et al. A 5' splice region G--&gt;C mutation in exon 3 of the human beta-spectrin gene leads to decreased levels of beta-spectrin mRNA and is responsible for dominant hereditary spherocytosis (spectrin Guemene-Penfao). Br J Haematol 1998; 100:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/64\">",
"      Becker PS, Tse WT, Lux SE, Forget BG. Beta spectrin kissimmee: a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1. J Clin Invest 1993; 92:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/65\">",
"      Hassoun H, Vassiliadis JN, Murray J, et al. Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site precludes spectrin attachment to the membrane in hereditary spherocytosis. J Clin Invest 1995; 96:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/66\">",
"      Hassoun H, Vassiliadis JN, Murray J, et al. Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Blood 1996; 87:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/67\">",
"      Maciag M, P��ochocka D, Adamowicz-Salach A, Burzy��ska B. Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol 2009; 146:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/68\">",
"      Tse WT, Gallagher PG, Jenkins PB, et al. Amino-acid substitution in alpha-spectrin commonly coinherited with nondominant hereditary spherocytosis. Am J Hematol 1997; 54:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/69\">",
"      Wichterle H, Hanspal M, Palek J, Jarolim P. Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest 1996; 98:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/70\">",
"      Yawata Y, Yawata A, Kanzaki A, et al. Electron microscopic evidence of impaired intramembrane particles and instability of the cytoskeletal network in band 4.2 deficiency in human red cells. Cell Motil Cytoskeleton 1996; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/71\">",
"      Bouhassira EE, Schwartz RS, Yawata Y, et al. An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON). Blood 1992; 79:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/72\">",
"      Takaoka Y, Ideguchi H, Matsuda M, et al. A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). Br J Haematol 1994; 88:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/73\">",
"      Kanzaki A, Yasunaga M, Okamoto N, et al. Band 4.2 Shiga: 317 CGC--&gt;TGC in compound heterozygotes with 142 GCT--&gt;ACT results in band 4.2 deficiency and microspherocytosis. Br J Haematol 1995; 91:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/74\">",
"      Matsuda M, Hatano N, Ideguchi H, et al. A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame). Hum Mol Genet 1995; 4:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/75\">",
"      van den Akker E, Satchwell TJ, Pellegrin S, et al. Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2). Haematologica 2010; 95:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/76\">",
"      Jarolim P, Palek J, Rubin HL, et al. Band 3 Tuscaloosa: Pro327----Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2. Blood 1992; 80:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/77\">",
"      Rybicki AC, Qiu JJ, Musto S, et al. Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid--&gt;lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore). Blood 1993; 81:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/78\">",
"      Inoue T, Kanzaki A, Kaku M, et al. Homozygous missense mutation (band 3 Fukuoka: G130R): a mild form of hereditary spherocytosis with near-normal band 3 content and minimal changes of membrane ultrastructure despite moderate protein 4.2 deficiency. Br J Haematol 1998; 102:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/79\">",
"      Kanzaki A, Hayette S, Morl&eacute; L, et al. Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis. Br J Haematol 1997; 99:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/80\">",
"      Bustos SP, Reithmeier RA. Structure and stability of hereditary spherocytosis mutants of the cytosolic domain of the erythrocyte anion exchanger 1 protein. Biochemistry 2006; 45:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/81\">",
"      Nicolas V, Le Van Kim C, Gane P, et al. Rh-RhAG/ankyrin-R, a new interaction site between the membrane bilayer and the red cell skeleton, is impaired by Rh(null)-associated mutation. J Biol Chem 2003; 278:25526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8841/abstract/82\">",
"      Lopez C, M&eacute;tral S, Eladari D, et al. The ammonium transporter RhBG: requirement of a tyrosine-based signal and ankyrin-G for basolateral targeting and membrane anchorage in polarized kidney epithelial cells. J Biol Chem 2005; 280:8221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7077 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8841=[""].join("\n");
var outline_f8_40_8841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H508400\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H508524\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Membrane instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Splenic conditioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H509478\">",
"      - Effect of splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MOLECULAR PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ankyrin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Band 3 defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spectrin deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Beta-spectrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Alpha-spectrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pallidin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rh-associated glycoprotein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H508400\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7077|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/7/9334\" title=\"figure 1\">",
"      RBC membrane model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/40/33414\" title=\"figure 2\">",
"      RBC membrane protein mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7077|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 1\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/50/1836\" title=\"table 1\">",
"      RBC changes HS splenectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8842="Serum sickness and serum sickness-like reactions";
var content_f8_40_8842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serum sickness and serum sickness-like reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8842/contributors\">",
"     Mark H Wener, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8842/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/40/8842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/40/8842/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/40/8842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal features of serum sickness are rash, fever, and polyarthralgias or polyarthritis, which begin one to two weeks after first exposure to the responsible agent, and resolve within a few weeks of discontinuation. Although patients may appear very ill and uncomfortable during the acute febrile stage, the disease is self-limited and prognosis is excellent once the responsible drug is stopped.",
"   </p>",
"   <p>",
"    The originators of the term \"serum sickness\" are von Pirquet and Schick, who published a book with that title (Die Serumkrankheit) in 1905 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/1\">",
"     1",
"    </a>",
"    ]. The authors described an illness that developed in some patients after administration of horse serum that had been given as an antitoxin for the treatment of diphtheria and scarlet fever. They noted that there was a delay between administration of the horse serum and the development of the symptoms of serum sickness, and the delay was shorter if horse serum was administered again at a later time.",
"   </p>",
"   <p>",
"    This syndrome was later revealed to result from the generation of human antibodies to horse serum proteins, subsequent deposition of antigen-antibody (immune) complexes in tissues, and activation of the complement cascade. Complement activation and recruitment of leukocytes lead to the release of inflammatory mediators, including histamine, the mediator likely responsible for the urticarial lesions classically observed.",
"   </p>",
"   <p>",
"    Lack of clarity about the meaning of the term \"serum sickness\" arose because it has been used to describe a variety of different, although related, syndromes. As mentioned previously, the classic clinical syndrome is caused by immunization of the host (human) by heterologous (non-human) serum proteins and subsequent illness caused by formation of immune complexes. However, the term also has been used to describe syndromes of rash, arthritis, and fever with onset several days to weeks following administration of a drug, or in association with some infectious diseases. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Serum sickness-like reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic review will discuss serum sickness and serum sickness-like reactions, with an emphasis upon the biology and clinical features of serum sickness. A detailed discussion of hypersensitivity vasculitis, which has features similar to serum sickness, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4070?source=see_link\">",
"     \"Hypersensitivity vasculitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness is the prototypic example of the Gell and Coombs \"type III\" or immune complex mediated hypersensitivity disease (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/2\">",
"     2",
"    </a>",
"    ]. The reaction requires the presence of the antigen, coincident with antibodies directed against the antigen, leading to the formation of antigen-antibody or immune complexes. These should normally be cleared by the mononuclear phagocyte system, although if this system is not functioning well or is saturated by the immune complex load, then excess immune complexes may form in the circulation and deposit in tissues, or form directly in the involved tissues. The presence of immune complexes in parenchymal tissues triggers an inflammatory response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immune complex formation",
"      </strong>",
"      &mdash; Following primary immunization with a protein antigen, IgM antibodies typically begin to develop 7 to 14 days later, and IgG antibodies appear a few days after IgM [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/3\">",
"       3",
"      </a>",
"      ]. If the foreign protein is still present in the circulation when these antibodies appear, the antigen and antibodies may combine to form immune complexes. The traditional teaching about serum sickness implicated IgG as the predominant immunoglobulin in immune complex formation, although the timing suggests involvement of IgM-containing immune complexes after initial exposure to an antigen. Biopsies of lesional skin in patients with serum sickness from equine antithymocyte globulin (ATG) demonstrated IgM, IgA, and IgE, although not IgG, supporting the role of immune complexes containing immunoglobulin classes other than IgG in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The ratio of antigen to antibody is critical to the type of immune complex formed. The Heidelberger precipitin curve for the formation of antigen-antibody complexes demonstrates that small immune complexes form under conditions of excess antigen or excess antibody (eg, Ag1Ab1 or Ag2Ab1) (",
"      <a class=\"graphic graphic_figure graphicRef68456 \" href=\"UTD.htm?14/41/15007\">",
"       figure 1",
"      </a>",
"      ). These small complexes are inefficient at activating complement or binding to low affinity Fc receptors and cause minimal or no damage if deposited in the tissues. However, intermediate-sized or large immune complexes (eg, Ag5Ab5) that deposit in tissues are able to activate complement and recruit inflammatory cells more efficiently.",
"      <br/>",
"      <br/>",
"      Complement activation",
"      <strong>",
"      </strong>",
"      leads to the formation of complement fragments, including C3a, a potent \"anaphylatoxin\" that causes mast cell degranulation, histamine release, and the development of urticarial lesions. The complement fragment C5a is a potent chemoattractant for neutrophils. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Complement activation also facilitates clearance of the immune complexes by coating soluble immune complexes with complement fragments. The complement-coated immune complexes then bind to erythrocytes that express the receptor for fragments of C3 (complement receptor 1), on their surfaces. Erythrocyte-bound immune complexes are subsequently cleared by the mononuclear phagocyte system (primarily in the spleen and Kupffer cells of the liver). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"       \"Regulators and receptors of the complement system\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immune complexes, both with and without complement fragments, are also cleared from the circulation as soluble complexes by binding to receptors for the Fc-portion of IgG (Fc gamma R or Fc&gamma;R) on cells of the mononuclear phagocyte system.",
"     </li>",
"     <li>",
"      <strong>",
"       Complement-independent mechanisms",
"      </strong>",
"      &mdash; Subsequent studies suggested that complement-independent mechanisms were also involved in the pathophysiology of serum sickness. Studies of experimental serum sickness and other immune complex diseases have been performed in mice that were genetically manipulated to disable the complement system",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      remove cellular receptors for the Fc portion of IgG (Fc&gamma;R) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. These studies revealed that in mice, a functioning complement system is not necessary to generate serum sickness, although intact Fc&gamma; receptors are. Immune complexes in tissues can react directly with Fc&gamma; receptors on neutrophils, mast cells, and phagocytes, leading to release of cytokines, histamine, and other inflammatory mediators, and formation of characteristic pathological lesions, even in the absence of complement. Additional studies have shown that immune complexes acting via the related Fc&gamma; receptor,",
"      <strong>",
"      </strong>",
"      Fc&gamma;RII, can have an inhibitory and immunomodulatory function [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Resolution",
"      </strong>",
"      &mdash; Serum sickness resolves when the antigen is entirely removed from the serum. The course of illness may be protracted if the culprit agent has been administered as a depot or sustained release form [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/11\">",
"       11",
"      </a>",
"      ]. Animal models of chronic serum sickness, in which intermittent injections of foreign proteins were repeated over time, led to fatal renal failure in some animals [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Recurrence",
"      </strong>",
"      &mdash; Serum sickness may develop more rapidly if a previously immunized patient is reexposed to the culprit antigen. Rather than requiring 7 to 14 days for the development of IgM antibodies, the amnestic IgG response to a recall antigen can begin within 12 to 36 hours. Typically, the same process then occurs more acutely and severely. If the patient still has IgG or IgE antibodies resulting from a previous exposure when exposed to the drug or serum again, an immediate reaction such as an acute anaphylactoid reaction may occur, leading to a mixed clinical picture. In theory, this could result from activation of mast cells or leukocytes by complement split products (ie, the anaphylatoxins C3a, C5a) via IgG immune complexes, or direct mast cell activation via IgE cross-linking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"       \"Complement pathways\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum sickness-like reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs (especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    and anti-seizure medications) can cause reactions that clinically resemble classical serum sickness, but are believed to be caused by different mechanisms. Serum sickness-like reactions also occur following infections (especially streptococcal and some viral infections) and a variety of vaccines. The pathogenesis is not well understood, although it likely does NOT depend upon high titers of antibodies and circulating immune complexes, as in classical serum sickness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antibiotic,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"       cefaclor",
"      </a>",
"      , can cause a reaction with features similar to serum sickness (ie, fever, rash, arthralgias, and possibly other symptoms), typically beginning one to three weeks after initial administration. One study demonstrated that metabolites of cefaclor produced in vitro were found to be toxic for lymphocytes and that the predisposing drug metabolism has a familial distribution and is thus presumptively genetically influenced [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/13\">",
"       13",
"      </a>",
"      ]. This type of reaction, in which drug metabolites may have a direct toxic effect on cells and lead to idiosyncratic, delayed drug reactions has been described for other medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It has been suggested that the term \"serum sickness-like disease\" should be replaced by \"urticaria with arthritis\" to describe this drug-induced syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/16\">",
"       16",
"      </a>",
"      ], although this has not become common practice. Other terms proposed include \"benign iatrogenic vasculitis\" and \"urticaria-arthralgia syndrome\" [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A serum sickness-like reaction that occurs days after drug administration may be seen in some patients who receive prolonged, high-dose intravenous penicillin. This may be caused by drug-specific immune complexes, rather than complexes containing heterologous serum proteins. Small drug molecules, or their reactive metabolites, may serve as haptens that bind covalently to serum proteins such as albumin, and result in an antibody response either to the hapten or the hapten-protein conjugate [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/14\">",
"       14",
"      </a>",
"      ]. Note that the same patients may develop immediate hypersensitivity, which could be mediated by IgE or IgG, and present with acute urticaria or an",
"      <span class=\"nowrap\">",
"       anaphylactic/anaphylactoid",
"      </span>",
"      reaction, as well as a later serum sickness-like reaction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"       \"Drug eruptions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The term \"serum sickness\" has also been used in the past to describe an immune complex disease associated with infectious agents. As an example, acute hepatitis B infection may present with rash, polyarthritis, and fever in the preicteric phase [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/18\">",
"       18",
"      </a>",
"      ]. Use of the term in this way is no longer common and is not recommended if a specific viral illness can be identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications and other therapeutic agents are the most common cause of serum sickness and serum-sickness like reactions. However, the overall incidence of these reactions is not well documented and varies considerably depending upon the medication in question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Agents causing serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical serum sickness is caused by administration of a protein antigen from a non-human species, as discussed previously. In the United States, use of heterologous antitoxins is relatively infrequent, although still central to the treatment of snake bite or rabies exposure. A meta-analysis reported that serum sickness occurs in 13 percent of patients receiving the sheep hyperimmune Fab antivenom used in the US after pit viper snake bites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of serum sickness in response to therapeutic murine monoclonal antibodies and chimeric antibodies (made by molecular engineering to combine some protein domains from human immunoglobulins and some of murine derivation) have appeared [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. The various heterologous proteins that have been associated with serum sickness are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef51122 \" href=\"UTD.htm?13/56/14220\">",
"     table 2",
"    </a>",
"    ). Repeatedly implicated agents include equine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    (ATG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (an anti-B-cell chimeric antibody) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/2,20,22-27\">",
"     2,20,22-27",
"    </a>",
"    ]. A similar immune-mediated rash, sometimes with features typical of serum sickness, has been seen in up to 3 percent of patients following therapy with anti-TNF alpha therapy using the chimeric murine-human monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , for Crohn's disease or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/21\">",
"     21",
"    </a>",
"    ]. Rarely, recurrent exposure to allogeneic human plasma during blood transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/28\">",
"     28",
"    </a>",
"    ], insect stings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/29\">",
"     29",
"    </a>",
"    ] or mosquito bites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/30\">",
"     30",
"    </a>",
"    ], or allergy immunotherapy extracts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] may cause serum sickness-type reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apparent risk factors include the dose, duration, and nature of the heterologous protein, as well as the age of the patient. Hypergammaglobulinemia may also be a risk factor, although this is based upon small numbers of cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dose",
"      </strong>",
"      &mdash; Higher doses of the administered agent are more likely than lower doses to result in serum sickness. This observation was made in the original description by von Pirquet, who noted that serum sickness developed in over 80 percent of patients receiving doses of over 100 mL of antiserum, while only 10 to 15 percent of patients receiving less than 20 mL of antiserum were afflicted. Similarly, higher doses of equine botulinum antitoxin and anti-snake venom were found to be more likely than lower doses to lead to serum sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"       \"Principles of snake bite management worldwide\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=see_link\">",
"       \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Nevertheless, even small doses of foreign protein may lead to the development of serum sickness in some situations. Some patients, for example, exposed to small amounts of bovine serum albumin administered during embryo transfer in the process of in vitro fertilization have been found to develop a serum sickness reaction to the bovine serum used for in vitro culture of the ova [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/35\">",
"       35",
"      </a>",
"      ]. Similarly, it has been postulated that some of the reaction to human diploid cell",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      may arise from reactions to the fetal bovine serum used to grow the cells in tissue culture (",
"      <a class=\"graphic graphic_table graphicRef51122 \" href=\"UTD.htm?13/56/14220\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &mdash; The incidence of serum sickness can be quite high with some agents. As examples, 85 percent of patients developed serum sickness in response to anti-thymocyte globulin (ATG) administered daily for 10 to 14 days for bone marrow failure in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/5\">",
"       5",
"      </a>",
"      ]. Forty to 80 percent of patients given antivenoms for snake bite may develop serum sickness [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/37-40\">",
"       37-40",
"      </a>",
"      ]. In contrast, a report from the Ukraine stated that anti-diphtheria serum caused serum sickness in only 1.5 percent of 2247 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Dosing schedule",
"      </strong>",
"      &mdash; Serum sickness can develop after a patient's initial exposure to a drug or after subsequent exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Intermittent exposure to a heterologous protein is associated with higher rates of serum sickness-like reactions, compared to continuous exposure, as illustrated by the following reports [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/21,43\">",
"       21,43",
"      </a>",
"      ]:Twenty-five percent",
"      <span class=\"nowrap\">",
"       (10/40)",
"      </span>",
"      of patients reinfused with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      following a long dosing hiatus developed a severe delayed reaction requiring glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/21\">",
"       21",
"      </a>",
"      ]. These reactions typically occurred 3 to 12 days following the second or third infusion.",
"      <br/>",
"      <br/>",
"      Delayed serum sickness-like reactions (arthralgias, fevers) developed in 15 percent of 52 adults given intermittent courses of infliximab therapy for Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/43\">",
"       43",
"      </a>",
"      ]. Delayed administration (greater than 20 weeks) of a second dose was associated with a higher risk of reactions. In this study, reactions were more likely to occur after a second dose than after subsequent doses of infliximab, and were less likely to occur if the time between administration of the first and second doses was less than 20 weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Age of patient",
"      </strong>",
"      &mdash; For some etiologies, adults may be at higher risk for serum sickness than children. Serum sickness in response to human and equine anti-rabies globulins were found in fewer than 0.5 percent of children under the age of 10 years, in a series of 72,000 patients (adults and children) receiving these preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/44\">",
"       44",
"      </a>",
"      ]. Although unusual in children overall, serum sickness-like disease has been reported as a relatively common etiology of acute arthritis in children under 16 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=see_link\">",
"       \"Evaluation of the child with joint pain or swelling\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypergammaglobulinemia and cryoglobulinemia",
"      </strong>",
"      &mdash; The development of serum sickness following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      may be more likely in patients with hypergammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients with hepatitis C-related mixed cryoglobulinemia vasculitis are at risk for serum sickness after rituximab infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Previous animal and insect exposure",
"      </strong>",
"      &mdash; Patients with prior exposure to rabbits may be at an increased risk of developing serum sickness after receiving rabbit anti-thymocyte globulin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/46\">",
"       46",
"      </a>",
"      ], and multiple repeated insect stings and bites may predispose to the rare phenomenon of serum sickness after stings [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Factors that reduce risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical modifications of the heterologous protein may decrease the risk of serum sickness reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of serum sickness reactions after administration of F(ab) fragments of sheep anti-digoxin to treat a digitalis overdose is very small, because F(ab) fragments rather than intact antibodies are administered and because the dose administered tends to be very low.",
"     </li>",
"     <li>",
"      Purification and enzymatic partial digestion of equine rabies antitoxin appear to decrease the risk of a reaction to that agent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of F(ab) fragments of sheep antivenom to treat Crotalidae snake bites is associated with lower rates of serum sickness and milder symptoms when reactions do occur, although the risk is not completely eliminated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another factor that may reduce the risk of serum sickness reactions is the concomitant administration of immunosuppressant drugs. It has been reported that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    prevents development of cutaneous vasculitis in treating rheumatoid arthritis patients with repeated doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . However, the mechanism of this interaction has not been characterized and the safety of this approach in general is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Preventing recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Agents causing serum sickness-like reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs, particularly antibiotics, are the leading cause of serum sickness-like reactions. Penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    are most commonly implicated, although many drugs have been associated with these reactions (",
"    <a class=\"graphic graphic_table graphicRef73703 \" href=\"UTD.htm?4/28/4557\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/11,25,51,52\">",
"     11,25,51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    .) As mentioned previously, viral infections can cause fever, rash, and arthralgias that mimic serum sickness like reactions.",
"   </p>",
"   <p>",
"    In children, serum sickness-like reactions are about 15-fold more likely with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    than with other cephalosporins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , even though all are structurally similar beta lactam antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Among children under five years of age treated with cefaclor, serum sickness-like reactions have been reported to occur in 0.024 to 0.2 percent of courses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/17\">",
"     17",
"    </a>",
"    ]. About 50 percent of patients were hospitalized, although the outcomes were universally favorable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6728679\">",
"    <span class=\"h2\">",
"     Signs and symptoms of serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of serum sickness are rash, fever, malaise, and polyarthralgias or polyarthritis, which occur one to two weeks after first exposure to the responsible agent, and resolve within a few weeks of discontinuing the drug. In patients who have been previously exposed to the agent, the syndrome starts earlier (ie, within one to seven days of receiving the inciting agent) and the illness has a more severe and \"explosive\" onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dermatologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of serum sickness are variable. Almost all patients diagnosed with serum sickness develop a pruritic rash, which is often the earliest clinical feature. The mucous membranes are not involved, which can be a useful feature in distinguishing serum sickness from clinically similar conditions. There may be urticarial lesions, which are typically longer-lasting than hives from other causes (",
"    <a class=\"graphic graphic_picture graphicRef52352 \" href=\"UTD.htm?10/17/10512\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rash often starts in the region around the injection site if a drug was administered locally by intramuscular or subcutaneous injection (as was typical for equine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    described by von Pirquet).",
"   </p>",
"   <p>",
"    The most characteristic rash is an urticarial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serpiginous macular rash that starts in the anterior lower trunk, groin, periumbilical, or axillary regions, and spreads to involve the back, upper trunk, and extremities. Skin changes may be prominent at the lateral aspect of the feet and hands, at the junction of the sole and side of the foot, or the border between the palm and dorsal skin of the fingers and hands (",
"    <a class=\"graphic graphic_picture graphicRef78783 \" href=\"UTD.htm?42/43/43711\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61556 \" href=\"UTD.htm?34/7/34929\">",
"     picture 3",
"    </a>",
"    ). This rash may be unique to serum sickness, and was first described in patients who develop serum sickness in response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/40/20102?source=see_link\">",
"     horse antithymocyte globulin",
"    </a>",
"    (ATG) administered as part of an immunosuppressive regimen used to treat aplastic anemia and other forms of bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other skin manifestations may include palpable purpura, morbilliform rashes, papules, or maculopapular lesions. Palmar erythema, livedo reticularis, and periungual hemorrhages have also been described. Erythema multiforme-type rashes with cyclic erythema can occur. Frankly vasculitic rashes are uncommon. The rashes generally last a few days to two weeks. Ulcers, secondary infection, or scarring do not occur. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients diagnosed with serum sickness develop fever, which is usually &gt;38.5&ordm;C. The fever of serum sickness is characterized by high spikes that return to normal within the same day. Rigors are unusual. The fever is remittent, but has no predictable temporal pattern. Malaise preceding and during the fever is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"     \"Drug fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rheumatic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthralgias are a characteristic, but inconstant feature of serum sickness, appearing in approximately two-thirds of patients. The joints commonly involved include the metacarpophalangeal joints, knees, wrists, ankles, and shoulders, although pain in the spine and temporomandibular joints are also described.",
"   </p>",
"   <p>",
"    While tenderness to palpation and movement are common and may be severe, swelling and erythema due to arthritis occur in only a minority of patients. The joint involvement tends to occur after the rash has started, and resolves before the rash has resolved. Myalgias in the arms and thighs may also occur. Jaw pain is also reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/46,56\">",
"     46,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Less common features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other, less common features of serum sickness include nonspecific headache and blurred vision, edema (including facial or peripheral edema), lymphadenopathy (particularly in regional lymph nodes draining the site of injection of the protein",
"    <span class=\"nowrap\">",
"     antigen/immunogen),",
"    </span>",
"    splenomegaly, anterior uveitis, and peripheral neuropathy, including Guillain-Barr&eacute; syndrome. Rarely the inflammatory process of serum sickness may be sufficiently intense to lead to long-term sequelae, such as persistent neuropathy, but the inflammatory process is self-limited if the offending antigen is removed.",
"   </p>",
"   <p>",
"    A variety of gastrointestinal manifestations may occur, including bloating, cramps, nausea, and diarrhea and occasionally melena [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Signs and symptoms of serum sickness-like reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness-like reactions are generally less severe than classic serum sickness. They typically involve a constellation of signs and symptoms, which can include arthralgias, lymphadenopathy, and urticarial rash with or without fever. Fever, when present, is typically low-grade. Children with serum sickness-like reactions may present with acute onset of joint pain, often leading to inability to walk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=see_link\">",
"     \"Evaluation of the child with joint pain or swelling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete blood count frequently demonstrates neutropenia, with development of reactive, plasmacytoid lymphocytes. Mild thrombocytopenia may occur. Eosinophilia may be present, but is not prominent. Measures of non-specific acute phase reactants, including the erythrocyte sedimentation rate and C-reactive protein, are elevated during active serum sickness. Hypoalbuminemia may be present in patients with edema.",
"   </p>",
"   <p>",
"    During serum sickness, urinalysis demonstrates mild proteinuria in about one-half of patients; those with proteinuria may also develop transient mild hematuria without cellular casts. Occasionally, the serum creatinine is elevated up to about twice the baseline value, but renal dysfunction tends to resolve within a few days. Overt glomerulonephritis is rare. Renal involvement is unusual in serum sickness-like reactions due to medications.",
"   </p>",
"   <p>",
"    During severe episodes, complement measurements including C3, C4, and total hemolytic complement are depressed, reflecting complement consumption. Measures of circulating immune complexes, including the fluid-phase C1q binding test and the Raji cell assay, are typically elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. The changes in complement and immune complex levels do not closely parallel the clinical course of serum sickness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dermatopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histological features of the serum sickness rash are variable and not specific for serum sickness. In most cases, findings are similar to those seen in patients with urticaria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild perivascular infiltrates consisting of lymphocytes and histiocytes, in the absence of vessel necrosis, were the most typical findings in skin biopsies of patients who developed serum sickness from equine ATG [",
"      <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/4\">",
"       4",
"      </a>",
"      ]. Immunofluorescence microscopy demonstrated IgM and C3, although no IgG, as mentioned previously. It is possible that patients receiving ATG are not representative of all patients with serum sickness, because they are immunosuppressed by both ATG and glucocorticoids and often are neutropenic because of their underlying hematologic problem.",
"     </li>",
"     <li>",
"      Leukocytoclastic vasculitis with neutrophilic involvement and fibrinoid necrosis has been reported in a minority of patients. Immunohistochemical or immunofluorescence staining with specific antibodies may reveal the presence of IgG and C3 within the walls of small arterioles and capillaries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the diagnosis of serum sickness is made clinically based upon the characteristic pattern of acute or subacute onset of a compatible rash, fever, and severe arthralgias and myalgias disproportionate to the degree of swelling, all occurring after exposure to a potential offending agent. Identification of the offending agent can be difficult if patients are on multiple medications that can be associated with serum sickness-like reactions.",
"   </p>",
"   <p>",
"    An important early goal of the evaluation is the exclusion of infectious causes. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest that patients who appear moderately or severely ill, or who are not taking a medication that can be readily implicated as the culprit, be evaluated with the following laboratory tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count and differential",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate and C-reactive protein",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Serum chemistries, including blood urea nitrogen, creatinine, and liver function tests",
"     </li>",
"     <li>",
"      Complement studies, including CH50, C3, and C4",
"     </li>",
"     <li>",
"      Testing for specific infectious diseases, if indicated by the history or physical examination",
"     </li>",
"     <li>",
"      Appropriate viral or bacterial cultures if an infectious cause is suspected (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin biopsies are not usually necessary or helpful in confirming the diagnosis, since the findings are variable and not specific for serum sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of serum sickness and serum sickness-like reactions includes viral illnesses with exanthems, hypersensitivity vasculitis, acute rheumatic fever, acute meningococcal or gonococcal infection, systemic onset juvenile idiopathic arthritis (Still's disease), and other types of drug reactions. In children, Kawasaki's disease is an additional possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In patients of any age",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Viral exanthematous infections",
"      </strong>",
"      &mdash; Viral infections can cause fever, rash, malaise, myalgias and arthralgias, although joint complaints are usually not as prominent as in serum sickness. Viral infections that cause exanthems or urticaria can be particularly difficult to differentiate from serum sickness. The presence of mucosal lesions or pharyngeal lesions, which may be seen with viral infections, is atypical of serum sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=see_link\">",
"       \"Fever and rash in the immunocompetent patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypersensitivity vasculitis and urticarial vasculitis",
"      </strong>",
"      &mdash; The pathogenesis of hypersensitivity vasculitis, urticarial vasculitis, and serum sickness all involve pathogenic formation of immune complexes, and both clinical and pathogenic overlap occur between these conditions. Most patients with serum sickness do not develop frankly vasculitic rashes. Arthralgias and arthritis are typically more prominent in serum sickness than in primary vasculitis, although they may be present in both. Urticarial vasculitis can be associated with systemic lupus erythematosus or can be a primary disorder, often associated with hypocomplementemia and autoantibodies to the complement component C1q as part of the hypocomplementemic urticarial vasculitis syndrome. Children with Henoch-Sch&ouml;nlein purpura (IgA vasculitis) typically have prominent bloody diarrhea, a petechial rash, proteinuria, and arthritis, with IgA deposits present in the skin and renal biopsies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4070?source=see_link\">",
"       \"Hypersensitivity vasculitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute rheumatic fever",
"      </strong>",
"      &mdash; Patients with acute rheumatic fever typically have migratory arthritis with prominent joint swelling, in contrast to the simple arthralgias that characterize serum sickness. Cardiac murmurs, carditis, and a history and elevated serologic tests consistent with a recent streptococcal infection also suggest acute rheumatic fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Scarlet fever",
"      </strong>",
"      &mdash; The characteristic scarlatiniform rash of scarlet fever is rarely associated with serum sickness, and the &lsquo;strawberry tongue&rsquo; of scarlet fever is not seen in serum sickness. In scarlet fever, the rash occurs along with the acute streptococcal infection on the second or third day of illness, whereas the onset of the rash and fever of serum sickness occurs at least several days after exposure to the inciting drug. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link\">",
"       \"Complications of streptococcal tonsillopharyngitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lyme disease",
"      </strong>",
"      &mdash; The erythema migrans rash of Lyme disease is distinct from the rash of serum sickness, the typical monoarthritis of the knee seen in Lyme disease is not typical of serum sickness. A history of tick exposure would suggest the diagnosis of Lyme disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Disseminated gonococcemia or meningococcemia",
"      </strong>",
"      &mdash; Patients with meningococcemia are usually acutely ill with findings of meningitis. The skin findings of patients with these conditions often include cutaneous pustules or purpuric lesions containing the organism, whereas pustules are not seen in serum sickness (",
"      <a class=\"graphic graphic_picture graphicRef52107 \" href=\"UTD.htm?30/28/31168\">",
"       picture 4",
"      </a>",
"      ). Patients with disseminated gonococcal infection can have a localized septic arthritis with swelling atypical of serum sickness, but can also have polyarthritis with painful periarticular swelling that can be confused with the findings of serum sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"       \"Clinical manifestations of meningococcal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Reactive arthritis",
"      </strong>",
"      &mdash; Both reactive arthritis (formerly known as Reiter syndrome) and serum sickness patients develop fever and joint pain. Mucosal involvement (urethritis, stomatitis) and eye inflammation are common in reactive arthritis, and not in serum sickness. The skin lesions associated with reactive arthritis, such as circinate balanitis, are distinct from the typical skin findings of serum sickness. Joint swelling and the development of chronic or recurrent arthritis are prominent in reactive arthritis, although not in serum sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other drug reactions",
"      </strong>",
"      &mdash; Other drug reactions that may mimic serum sickness or serum sickness-like reactions include non-specific exanthems, urticaria, and generalized hypersensitivity reactions. The development of an IgE-mediated drug allergy can cause the onset of urticaria during a course of therapy. The concomitant presence of other allergic symptoms (such as throat tightness, wheezing, or acute anaphylaxis) may help discern the underlying process. If the culprit drug was penicillin or another beta lactam drug, then skin testing for IgE-mediated drug allergy may be possible after the reaction has resolved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema multiforme",
"      </strong>",
"      &mdash; The presence of target skin lesions and involvement of the palms, soles, and mucosal surfaces are characteristic features of erythema multiforme (",
"      <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"       picture 5",
"      </a>",
"      ). None of these is typical of serum sickness. Arthralgias are generally not prominent in erythema multiforme. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=see_link\">",
"       \"Fever and rash in the immunocompetent patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Stevens-Johnson syndrome",
"      </strong>",
"      &mdash; Stevens-Johnson syndrome and toxic epidermal necrolysis are potentially fatal drug hypersensitivity reactions that typically begin suddenly, with high fever, vesicular or bullous lesions on an erythematous background, and systemic illness (",
"      <a class=\"graphic graphic_picture graphicRef67632 \" href=\"UTD.htm?24/48/25345\">",
"       picture 6",
"      </a>",
"      ). In the earliest stages, these reactions could be confused with serum sickness-like reactions, although the later lesions of these severe reactions are distinct. Prompt discontinuation of possible culprit drugs is the most important immediate intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Still's disease",
"      </strong>",
"      &mdash; Still's disease (systemic onset juvenile idiopathic arthritis) may present with fever, arthralgias, oligoarthritis or periarthritis, and rashes. The rash of Still's disease is classically evanescent, appearing during the febrile phase of the circadian variations in body temperature associated with Still's disease, and then fading within a few hours (",
"      <a class=\"graphic graphic_picture graphicRef62959 \" href=\"UTD.htm?13/24/13711\">",
"       picture 7",
"      </a>",
"      ). In contrast, the rash of serum sickness is morphologically different and is usually more persistent. Still's disease is likely to continue or recur without treatment, whereas serum sickness resolves within a few weeks of discontinuing the offending agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult Still's disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other considerations in children",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The autoinflammatory syndromes (such as Familial Mediterranean fever, chronic infantile neurologic, cutaneous, and articular (CINCA) syndrome, neonatal-onset multisystem inflammatory disorder (NOMID)) present with fever, rashes, and arthritis, however these are recurrent disorders, rather than the acute self-limited reaction of serum sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kawasaki's disease &mdash; The presentation of fever, rash, and hand edema in children with Kawasaki's disease (KD) can mimic serum sickness. Peripheral extremity changes, including erythema of palms or soles or edema of hands or feet (acute phase), and periungual desquamation (convalescent phase) seen in Kawasaki's differ from the polyarthritis and arthralgias of serum sickness. Prominent mucosal disease in the mouth and conjunctiva are typical of Kawasaki's and unusual in serum sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based guidelines or controlled trials upon which to base therapy recommendations. The approach here is based upon the author's experience, as well as case reports and series in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/17,37,42,57,58\">",
"     17,37,42,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To determine common practices, a retrospective chart review examined the management of children presenting with reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    by emergency department pediatricians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/57\">",
"     57",
"    </a>",
"    ]. The most common treatment for serum sickness-like reactions was discontinuation of the culprit drug, combined with the prescription of both antihistamines and glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Withdrawal of culprit agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with minimal disease do not require treatment, other than withdrawing the offending agent. Typically, fever and arthralgias resolve and new skin lesions stop forming within 48 hours of this intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines may be sufficient for patients with pruritus and mild rash. Nonsteroidal antiinflammatory agents and analgesics may be used for low-grade fever and arthralgias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with higher fever (eg, temperature &gt;38.5&ordm;C), more severe arthritis and arthralgias, or more extensive rashes including extensive vasculitic rashes may be treated with short courses of glucocorticoids. The utility of glucocorticoids in the treatment of serum sickness and serum sickness-like reactions is based upon case reports and small observational series. These agents are usually administered orally (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/11,25,52\">",
"     11,25,52",
"    </a>",
"    ]. Sometimes even higher doses are used. Occasionally, patients who are very uncomfortable or who appear acutely ill may be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    in the range of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in one or two divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/42,59\">",
"     42,59",
"    </a>",
"    ]. Glucocorticoids can frequently be rapidly tapered, with the total duration of therapy less than one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19657308\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, plasmapheresis has been used to treat or prevent recurrent serum sickness attacks when implicating agents could not be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19657275\">",
"    <span class=\"h2\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms typically resolve within two weeks of removal of the offending agent, although in unusual cases, symptoms can persist for as long as two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/1\">",
"     1",
"    </a>",
"    ]. If glucocorticoids are used to treat acute symptoms, their withdrawal can unmask the ongoing disease process, leading to recurrent symptoms and signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Preventing recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once serum sickness or a serum sickness-like reaction develops, the drug that is responsible should be avoided, if possible. There is some controversy about whether related drugs can be administered safely. As an example, after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    -induced serum sickness-like reactions, administration of another cephalosporin is usually tolerated well, although some authorities recommend that all beta-lactam drugs be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/17,58\">",
"     17,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither skin tests nor any in vitro studies are able to predict initial or recurrent episodes of serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/47,61\">",
"     47,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If no alternative agents are available and re-treating with a drug that previously caused serum sickness is absolutely required, treatment with antihistamines or glucocorticoids may be helpful to prevent future episodes of serum sickness upon reexposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/40/8842/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic \"serum sickness\" describes the clinical syndrome caused by immunization of the host (human) by heterologous (non-human) serum proteins and subsequent illness caused by formation of immune complexes. Serum sickness-like reactions present as rash, arthritis, and fever beginning several days to weeks following administration of a drug. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic serum sickness is a Gell and Coombs \"type III\" or immune complex-mediated hypersensitivity disease (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"       table 1",
"      </a>",
"      ). Heterologous protein antigens combine with host immunoglobulins specific to those antigens. If the resultant immune complexes are not adequately cleared by the mononuclear phagocyte system, excess immune complexes form in (or are deposited in) tissues and trigger an inflammatory response. In contrast, the pathophysiology of serum sickness-like reactions is less well characterized and may vary depending upon the culprit agent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of heterologous &lsquo;foreign&rsquo; proteins can cause classic serum sickness (",
"      <a class=\"graphic graphic_table graphicRef51122 \" href=\"UTD.htm?13/56/14220\">",
"       table 2",
"      </a>",
"      ). Therapeutic murine monoclonal antibodies and chimeric antibodies, including equine antithymocyte globulin (ATG),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , have been implicated. Serum sickness-like reactions are most commonly caused by antibiotics, such as penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"       cefaclor",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , although a variety of medications have been associated with these reactions (",
"      <a class=\"graphic graphic_table graphicRef73703 \" href=\"UTD.htm?4/28/4557\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptoms of serum sickness are rash, fever, malaise, and polyarthralgias or polyarthritis, which occur one to two weeks after first exposure to the responsible agent and resolve within a few weeks of discontinuing the drug. In patients who have been previously exposed to the agent, the syndrome starts earlier (ie, within one to seven days of receiving the inciting agent) and the illness has a more severe and \"explosive\" onset. The rash is a pruritic urticarial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      morbilliform eruption. The mucosal membranes are not involved. Laboratory findings are variable. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of serum sickness and serum sickness-like reactions is made clinically, based upon the characteristic pattern of physical and laboratory findings occurring after exposure to a potential offending agent. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of these reactions primarily involves discontinuation of possible culprit agents. Typically, fever and arthralgias resolve and new skin lesions stop forming within 48 hours of this intervention. This is often all that is required for patients with mild symptoms. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further treatments depend upon the discomfort of the individual patient. Antihistamines may be administered for symptomatic relief of pruritus. Nonsteroidal antiinflammatory agents and analgesics may be given for symptomatic treatment of low-grade fever and arthralgias. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with higher fever (eg, temperature &gt;38.5&ordm;C), more severe arthritis and arthralgias, or extensive rashes, we suggest short courses of glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These are usually administered orally (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), although intravenous administration (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      in the range of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in one or two divided doses) may be considered in patients who appear acutely ill. This treatment can usually be tapered within the course of a week. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once serum sickness or a serum sickness-like reaction develops, the responsible drug should be avoided in the future. It is not clear that similar drugs must also be avoided. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Preventing recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     von Pirquet CF, Schick B. (Die Serumkrankheit). Serum Sickness, Schick B (Ed), Williams &amp; Wilkins, Leipzig (translation Baltimore 1905 (translation 1951).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/2\">",
"      Lawley TJ, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 1984; 311:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/3\">",
"      Vincent C, Revillard JP. Antibody response to horse gamma-globulin in recipients of renal allografts: relationship with transplant crises and transplant survival. Transplantation 1977; 24:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/4\">",
"      Bielory L, Yancey KB, Young NS, et al. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol 1985; 13:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/5\">",
"      Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore) 1988; 67:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/6\">",
"      Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994; 265:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/7\">",
"      Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/8\">",
"      Sylvestre D, Clynes R, Ma M, et al. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 1996; 184:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/9\">",
"      Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/10\">",
"      Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/11\">",
"      Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 2006; 26:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/12\">",
"      Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med 1971; 134:7s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/13\">",
"      Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/14\">",
"      Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/15\">",
"      Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/16\">",
"      Kunnamo I, Kallio P, Pelkonen P, Viander M. Serum-sickness-like disease is a common cause of acute arthritis in children. Acta Paediatr Scand 1986; 75:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/17\">",
"      Vial T, Pont J, Pham E, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother 1992; 26:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/18\">",
"      Lieberman P, Rice MC, Mallette JE Jr. Studies of urticaria and acute serum sickness with the C1q precipitin test. Arch Intern Med 1977; 137:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/19\">",
"      Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med 2012; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/20\">",
"      D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/21\">",
"      Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/22\">",
"      Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/23\">",
"      Schutgens RE. Rituximab-induced serum sickness. Br J Haematol 2006; 135:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/24\">",
"      Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005; 80:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/25\">",
"      Rana JS, Sheikh J. Serum sickness-like reactions after placement of sirolimus-eluting stents. Ann Allergy Asthma Immunol 2007; 98:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/26\">",
"      Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/27\">",
"      Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/28\">",
"      Saegeman V, Wynendaele W, Kerre S, et al. Transfusion-induced serum sickness. Transfusion 2009; 49:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/29\">",
"      Reisman RE, Livingston A. Late-onset allergic reactions, including serum sickness, after insect stings. J Allergy Clin Immunol 1989; 84:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/30\">",
"      Gaig P, Garc&iacute;a-Ortega P, Enrique E, et al. Serum sickness-like syndrome due to mosquito bite. J Investig Allergol Clin Immunol 1999; 9:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/31\">",
"      Cruz NV, Bahna SL. Fever, urticaria, lymphadenopathy, and protracted arthralgia and myalgia resistant to corticosteroid therapy. Allergy Asthma Proc 2011; 32:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/32\">",
"      Hunt KJ, Sobotka AK, Valentine MD, et al. Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978; 61:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/33\">",
"      Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/34\">",
"      Borden J, Fonkalsrud E, Newcomer V. Snake bite: treatment by isolation perfusion technique. Surgery 1961; 49:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/35\">",
"      Morales C, Bras&oacute; JV, Pellicer A, et al. Serum sickness due to bovine serum albumin sensitization during in vitro fertilization. J Investig Allergol Clin Immunol 1994; 4:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/36\">",
"      Warrington RJ, Martens CJ, Rubin M, et al. Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. J Allergy Clin Immunol 1987; 79:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/37\">",
"      LoVecchio F, Welch S, Klemens J, et al. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med 1999; 34:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/38\">",
"      Kunkel DB, Curry SC, Vance MV, Ryan PJ. Reptile envenomations. J Toxicol Clin Toxicol 1983- 1984; 21:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/39\">",
"      Shemesh IY, Kristal C, Langerman L, Bourvin A. Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome. Toxicon 1998; 36:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/40\">",
"      Jurkovich GJ, Luterman A, McCullar K, et al. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/41\">",
"      Vozianova ZhI, Chepilko KI. [Serum sickness in diphtheria]. Lik Sprava 1999; :126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/42\">",
"      Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/43\">",
"      Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/44\">",
"      Suwansrinon K, Jaijareonsup W, Wilde H, et al. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 2007; 101:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/45\">",
"      S&egrave;ne D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60:3848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/46\">",
"      Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis 2010; 55:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/47\">",
"      Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995; 21:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/48\">",
"      Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/49\">",
"      Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/50\">",
"      Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/51\">",
"      Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol 2006; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/52\">",
"      Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann Allergy Asthma Immunol 2001; 86:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/53\">",
"      Heckbert SR, Stryker WS, Coltin KL, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/54\">",
"      Stricker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/55\">",
"      King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health 2003; 39:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/56\">",
"      Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009; 29:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/57\">",
"      Joubert GI, Hadad K, Matsui D, et al. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol 1999; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/58\">",
"      Grammer LC. Cefaclor serum sickness. JAMA 1996; 275:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/59\">",
"      Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007; 13:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/60\">",
"      Bayraktar F, Akinci B, Demirkan F, et al. Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis. Diabet Med 2009; 26:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/40/8842/abstract/61\">",
"      Erffmeyer JE. Serum sickness. Ann Allergy 1986; 56:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2078 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8842=[""].join("\n");
var outline_f8_40_8842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Agents causing serum sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Factors that reduce risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Agents causing serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6728679\">",
"      Signs and symptoms of serum sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dermatologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rheumatic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Less common features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Signs and symptoms of serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dermatopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In patients of any age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other considerations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Withdrawal of culprit agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19657308\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19657275\">",
"      Resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Preventing recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2078|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/41/15007\" title=\"figure 1\">",
"      Precipitin curve immune complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2078|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/17/10512\" title=\"picture 1\">",
"      Serum sickness urticarial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/43/43711\" title=\"picture 2\">",
"      Serum sickness foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/7/34929\" title=\"picture 3\">",
"      Serum sickness hands feet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/28/31168\" title=\"picture 4\">",
"      Acute meningococcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 5\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25345\" title=\"picture 6\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13711\" title=\"picture 7\">",
"      Systemic onset JIA rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/56/14220\" title=\"table 2\">",
"      Het proteins and serum sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/28/4557\" title=\"table 3\">",
"      Drugs implicated in serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11320?source=related_link\">",
"      Clinical manifestations and diagnosis of adult Still's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=related_link\">",
"      Fever and rash in the immunocompetent patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4070?source=related_link\">",
"      Hypersensitivity vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_40_8843="Reversible causes of ileus";
var content_f8_40_8843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potentially treatable causes of ileus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abdominopelvic abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anastomotic leaks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendicitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholecystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoperitoneum or retroperitoneal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opiates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uremia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8843=[""].join("\n");
var outline_f8_40_8843=null;
var title_f8_40_8844="Inotropic agents in postop";
var content_f8_40_8844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inotropic drugs used in the treatment of low cardiac output in the post-operative cardiac surgical patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose range (adult)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Actions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Dopamine",
"       </td>",
"       <td>",
"        3 to 5 mcg/kg/min",
"       </td>",
"       <td>",
"        Renal vasodilator/variable hemodynamic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 to 10 mcg/kg/min",
"       </td>",
"       <td>",
"        Vasodilator/inotropy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 mcg/kg/min",
"       </td>",
"       <td>",
"        Vasoconstrictor",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dobutamine",
"       </td>",
"       <td>",
"        5 to 20 mcg/kg/min",
"       </td>",
"       <td>",
"        Inotropy &gt; vasodilator",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Milrinone*",
"       </td>",
"       <td>",
"        <p>",
"         0.25 to 0.75 mcg/kg/min",
"        </p>",
"        <p>",
"         (optional loading dose: 50 mcg/kg over 10 mins)",
"        </p>",
"       </td>",
"       <td>",
"        Vasodilator &gt; inotropy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Epinephrine",
"       </td>",
"       <td>",
"        0.01 to 0.3 mcg/kg/min or 1 to 20 mcg/min",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Inotropy/vasodilator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;0.3 mcg/kg/min or &gt;20 mcg/min",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Vasoconstrictor",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Norepinephrine",
"       </td>",
"       <td>",
"        0.01 to 0.03 mcg/kg/min or 1 to 2 mcg/min",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Inotropy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;0.03 mcg/kg/min or &gt;2 mcg/min",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Vasoconstrictor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * With dose alteration if necessary for renal insufficiency.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      For &asymp;70 kg body weight adult.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8844=[""].join("\n");
var outline_f8_40_8844=null;
var title_f8_40_8845="Glycemic index and load values";
var content_f8_40_8845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary glycemic indices and glycemic load for the top 20 carbohydrate-contributing foods in the Nurses' Health Study in 1984",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Foods",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glycemic index*, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate per serving, g",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glycemic load per serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Cooked potatoes (mashed or baked)",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. White bread",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Cold breakfast cereal",
"       </td>",
"       <td>",
"        Varies by cereal",
"       </td>",
"       <td>",
"        Varies by cereal",
"       </td>",
"       <td>",
"        Varies by cereal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Dark bread",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Orange juice",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Banana",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. White rice",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Pizza",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Pasta",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. English muffins",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Fruit punch",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Cola",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Apple",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14. Skim milk",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15. Pancake",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16. Table sugar",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17. Jam",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18. Cranberry juice",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19. French fries",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20. Candy",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Standard reference is white bread, which has a glycemic index of 100 percent. All other glycemic index values are relative to white bread.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Liu S, Willett WC. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002; 4:454.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8845=[""].join("\n");
var outline_f8_40_8845=null;
var title_f8_40_8846="Silent ischemia stable angina";
var content_f8_40_8846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Symptomatic versus silent ischemia in stable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nine studies of patients with stable angina showing that silent ischemia (documented on ambulatory monitoring) is more common than symptomatic ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8846=[""].join("\n");
var outline_f8_40_8846=null;
var title_f8_40_8847="Complete bicornuate uterus";
var content_f8_40_8847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus bicornuate: Complete (division down to internal os)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_40_8847=[""].join("\n");
var outline_f8_40_8847=null;
